ࡱ> oqjklmn#` Rbjbjmm2```t\\\8(ttz*(RRR111>@@@@@@$hTdq`-1dRRՕ111RR`R>1>11f~p>"`R  X\n6DZ0JQ+QQ`p 11sl111dd`1j111tttDw}ittt}ttt 2008t^LykSu{|YePgeXRQ[ ,{NR $Re $N{ Some sleep drugs do more than make you sleep The United States Food and Drug Administration1 has ordered companies to place strong new warnings on thirteen drugs that treat sleep disorders. It also ordered the makers of the sleeping pills to provide information for patients explaining how to safely use the drugs. Last Wednesday, the FDA announced that some of these drugs can have unexpected and dangerous effects. These include the risk of life-threatening allergic reactions. They also include rare incidents of strange behavior. These include people cooking food, eating and even driving while asleep. The patients later had no memory of doing these activities while asleep. Last year, a member of the United States Congress2 said he had a sleep-driving incident. Patrick Kennedy, a representative from Rhode Island,3 crashed his car into a security barrier near the building where lawmakers meet. The accident happened in the middle of the night and no one was hurt. Mr. Kennedy said he had earlier taken a sleep medicine. He said he was also being treated with a stomach sickness drug that can cause sleepiness. The Food and Drug Administration did not say in its announcement how many cases of sleep-driving it has documented. However, the New York Times4 reported last year about people who said they had strange sleep events after taking the drug Ambien. Some reported sleep-driving and sleep-walking. Others said they found evidence after waking in the morning that they had cooked food or eaten in their sleep. But they had no memory of carrying out the activities. A Food and Drug Administration official says that these serious side effects of sleep disorder drugs appear to be rare. But, he also said there are probably more cases than are reported.5 He said the agency believes the risk of such behaviors could be reduced if people take the drugs as directed and do not drink alcohol while taking the drugs. The Food and Drug Administration has advised drug companies to carry out studies to investigate the problem. ͋Gl 00disorder n. x }qNuu 00allergic adj. S^'`v ǏOe'`v 00incident n. vPSNN \NN 00representative n. Nh 00crash v. O xd 00lawmaker n. zl 6R[l_$\czlYXTbXT 00sickness n. uuv`_ UTT 00stomach n. À 00sleepiness n. ff2kaw 00document vt. 9hnc& N[Pge6R\O lʑ United States Food and Drug Administration (FDA)VߘTSoT{t@\ United States CongressVVO Rhode IslandW_\V] T New York Times~~eb 5. But, he also said there are probably more cases than are reported. NǏ N_NS S[EuOkb[vY0 la,gS-Nthanv(ul0thanTbޏcNN*NSP[ S/ftSl g;N f[/gLu[dk g$NylNy:Nthan/fsQ|N͋ [,g(WNS-N\ON*NSP[bRSNyR:NthanN:Nޏc͋ TbweuNSP[vS_bR0 w{|f6q/fv0 B Ppe,{Nk0R ߘ(u'Yϑ}v܅ُy iirvmTir 1\O[ gTNkS0R}v܅cؚvR ُN/fckbv0ygv\O(u v^l g[Lv0 C Ppe,{NkS~R-N+T g}v܅ v^l gvQ[R{| g؏/fl g0 ,{ NR ib'YaN[bSP[ $N{ Napping to a Healthier Heart? 1 Researchers say they have developed a simple test that can tell if a person with heart disease is likely to suffer a heart attack.2 The test measures levels of a protein in the blood. The researchers say people with high levels of this protein are at high risk of heart attack, heart failure3 or stroke. Kirsten Bibbins-Domingo of the University of California in San Francisco led the team. For about four years, they studied almost one thousand patients with heart disease. The researchers tested the heart disease patients for a protein called NT-proBNP.4 Patients with the highest levels were nearly eight times more likely than those with the lowest levels to have a heart attack, heart failure or stroke. The researchers say the presence of high levels of the protein in the blood shows that the heart muscle is under pressure in some way. The study involved mostly men, so the researchers could not say for sure5 that the results are also true for women. They say the patients with the highest levels of NT-proBNP were older and had other problems like diabetes or high blood pressure. Other researchers say more studies are needed to confirm if knowing the protein levels of a heart patient should affect that person's treatment. They also would like to know if more aggressive treatment6 could reduce the patient's chance of a heart attack or stroke. The study appeared in the Journal of the American Medical Association.7 Could a little sleep during the middle of the day reduce the risk of a heart attack? An unrelated study earlier this month in the Archives of Internal Medicine8 suggests that the answer may be yes. In countries like the United States, afternoon naps are mostly for children. But they are common for adults in Mediterranean countries. And these countries generally have lower rates of heart disease. So scientists in the United States and Greece wondered if naps could play a part. Twenty-three thousand healthy adults took part in the study by Harvard University and the University of Athens.9 Those who took thirty-minute naps three times a week had a thirty-seven percent lower risk of death from heart problems than people who did not take naps. The researchers say napping may improve heart health by reducing stress. They say the research suggests that naps are especially good for working men. But they say not enough female subjects died during the study to judge the benefits for women. ͋Gl nap n. vi. (}v)Y)\aw SbvawHSɉ attack n. (uu)S\O failure n. pz stroke n. -NΘ muscle n. diabetes n. |?\u confirm vt. nx ۏNek[ archive n. (8^(u Ype) chHhchHh[ Mediterranean adj. 0W-Nwmv Greece n. ^J stress n. SR subject n. S[ lʑ 1. Napping to a Healthier Heart? HSawSNO_feP^Tto(Wُ̑h:y0Rgy~gbHeg0 2. heart attack_uS\O 3. heart failure_Rpz 4. NT-proBNPNz-W)RSbN+gzMR)R 0[/f_-NvNySRc:yVP[ ggb:NKmQ_ulR_vuSh_ir0 5. for surenx[ keu0W 6. aggressive treatment_c$O'`luaggressiveSa/f g;eQ'`v Oeuv 7. American Medical Association (AMA) V;Sf[O 8. Archives of Internal MedicineQy;Sf[chHh 9. Harvard UniversityV T[O'Yf[ University of Athens ^J ŖxQ'Yf[ ~`N 1. Paragraph 2 2. Paragraph 3 3. Paragraph 5 4. Paragraph 6 A Effects of napping in females still uncertain B Older males have higher levels of NT-proBNP C Development of a simple but important test D Evidence of positive relationship between napping and heart disease E How to control the levels of NT-proBNP F Effects of NT-proBNP on heart disease  5. According to some researchers, by measuring the levels of NT-proBNP in the blood people may know 6. If a person has a high level of NT-proBNP 7. People who take regular afternoon naps 8. So far there have not been definite data to confirm A0where fewer people die from heart problem. B0whether they have the risk of heart attack, heart failure or stroke. C0would probably have lower rates of heart disease. D0how to test a person s NT-proBNP level in the blood by himself. E0his heart muscle would be under pressure in some way. D0that napping is of great benefit to women too. T{HhN F ,gkTb$NS0R Ǐhg_uNvNT-proBNP4ls^ Ss4ls^gؚvuNN4ls^gNOvuNKN`_uvS'`v]яkQ P0 B ,gk0R NN@bgv/f7u'` v^Sst^7u'`N` g|?\uTؚ@SNT-proBNPv4ls^gؚ0 D ,gk0R 0W-NwmV[vbt^NnfM gHSaw N`_uvksNO0T[O'Yf[TŖxQ'Yf[vxvzf khTHSaw N!k0k!k30RvNk[hQ NHSawvN{kN_uvks\37%0 A gTNk HSaw[]\Ov7u'`$\vQ gv }6qge{kNvsY'`v^ NY FOHSaw[sY'`vvYezv^l g~QN*Nfnx~0 B T{HhegnN,{Nkv,{N0 NS0 E T{HhegnN,{ Nk,{NS0 C T{HhegnN,{Nk,{ N0VST勵kgTNS0 F T{HhegnN,{ Nk,{NSTezvgTNSv0 Pregnant women warned about ACE1 inhibitor Some of the most commonly used medicines for high blood pressure are drugs called ACE inhibitors. Doctors have given these drugs to patients for twenty-five years. A government study in the United States found that the use almost doubled between1995 and 2000. Doctors have known for years that women should not take ACE inhibitors during the last six months of pregnancy. The medicine can injure the baby. ACE inhibitors, though, have been considered safe when taken during the first three months. But a new study has found that women who take these drugs early in their pregnancy still increase the risk of birth disorders.2 The study shows that, compared to others, their babies were almost three times as likely to be born with major problems.3 These included problems with the formation of the brain and nervous system and holes in the heart. The researchers say they found no increased risk in women who took other blood pressure medicines during the first three months. Researchers at Vanderbilt University in Tennessee and Boston University did the study. The New England Journal of Medicine4 published the results. The researchers studied the records of almost thirty thousand births between 1985 and 2000. Two hundred nine babies were born to women who took ACE inhibitors during the first three months of their pregnancies. Eighteen of the babies, or almost nine percent, had major disorders. ACE inhibitors are often given to patients with diabetes. But diabetes during pregnancy can result in birth defects.5 So the study did not include any women known to be diabetic. ACE inhibitors suppress a protein called angiotensin-converting enzyme, or ACE. This enzyme produces a chemical in the body that makes blood passages narrow. The drugs increase the flow of blood so pressure is reduced. New drugs are tested on pregnant animals to see if they might cause birth defects in humans. But experts say these tests are not always dependable. The United States Food and Drug Administration6 helped pay for the study. The F.D.A. says women who might become pregnant should talk with their doctor about other ways to treat high blood pressure. ͋Gl pregnant adj. `U[v warn vt. fJT inhibitor n. b6RBR pregnancy n. `U[ diabetes n. |?\u diabetic adj. |?\uv n. |?\u` suppress vt. b6R protein n. ˆ}v( dependable adj. S`v lʑ ACE (angiotensin-converting enzyme )@{'} _lSv birth disordersHQ)Y'`uu 3.0The study shows that, compared to others, their babies were almost three times as likely to be born with major problems. ُyxvzhf YgNvQNtZ?Qvk ُNtZ?Q(WQue`'YuvS'`QNN/fNNv N P0compare to(WV-N_N g compared withN...vk va`0SY problem(W;Sf[e.s-N8^8^(uegcuu0 4. New England Journal of MedicineeeQSQ}l0IQ~0p0lsTI{ 4. Researchers are studying ways to program them to identify diseases by lighting up in the presence of a targeted molecule. xvzNXTck(Wxvz:N[N zvel NOYg gvRP[X[(WeǏSIQuu0light uppopSIQ0targeted moleculevRP[0 5. National Institutes of Health (NIH)VzkSuxvzb 6. side effectoR\O(u 7. compared to larger particlesYgN'YNpv|kwegv݋0ُ/fN*NǏSR͋w \OagNr0compare& to(WV_NSNh:ycompare& withva`0 ~`N 1. Which of the following uses of nanotechnology is NOT mentioned in the passage? To make beauty products and dirt-resistant clothing. To produce better and lighter building materials. To help more accurately diagnose diseases. To help more effectively treat diseases. 2. How can quantum dots be used to confirm diseases? A) By traditionally looking at a person's blood under a microscope. B) By letting a person take some kind of medicine. C) By lighting up in the presence of a targeted molecule. D) By subjecting a person to an X-ray examination. 3. How can nanotechnology be used to make a drug more effective? A) By making a drug target the focus of a disease. B) By changing the structure of the body cells. C) By lowering the side effects caused by a drug. D) By letting a patient take a dose as large as possible. 4. The following developing countries are doing very well scientific research on nanotechnology EXCEPT . A) China B) Brazil C) Iran D) India 5. Which of the following is the possible risk in using nano-materials mentioned in the passage? A) They may cause some damage to the body cells. B) They are harmful materials themselves. C) They may store in the body. D) They may behave differently in the body and the environment. T{HhN 1. B0,g yA(W,{Nk,{ NSc0R yC(W,{NkPpe,{NST,{Vk,{NSc0R yDR(W,{Vk,{N0 N0VSc0R S g yBhQeGW*gcS0 2. C0,{ NkgT$NS0R YgX[(WvRP[v݋ ϑP[p1\OSIQ Ndkuu ُck/f,gT{Hh0 3. A0,{VkhQk(W~s|b/gYUOcؚoiruHe -N_1\(WN~s|b/gOoir[Quuuvpez-N[E/f>N]~xSvlLvo:NO N cؚoiruHe0 4. C0,{Nk,{NS]~__nZi vQ-Nv^l gIran0 5. D0,{Nk,{ N0VS0R ~s|Pgev|(WSOQT(WSOYsX-N\O(uS N*YN7h VdkSX[(WgyqSi'`0vQ[YKNa؏X[(W*gwpe @bNTNSMbfYbeQNOdn[NvqSi'`0 Multivitamins urged for all pregnant women A recent study in Tanzania found that when pregnant women took vitamins every day, fewer babies were born too small. Babies that weigh less than two and one-half kilograms at birth have a greater risk of dying. Those that survive are more likely to experience problems with their development. And experts say that as adults they have a higher risk of diseases including heart disease and diabetes. The World Health Organization1 estimates that every year twenty million babies are born with low birth weight. Nine out of ten of them are born in developing countries. The new study took place in Dar es Salaam.4,200 pregnant women received multivitamins. The pills contained all of the vitamins in the B group along with2 vitamins C and E. They also contained several times more iron and folate than the levels advised for women in developed nations. Pregnant women especially in poor countries may find it difficult to get enough vitamins and minerals from the foods in their diet. The scientists compared the findings with results from a group of4,000 women who did not receive the vitamins. A report by the scientists, from the United States and Tanzania, appeared in the New England Journal of Medicine.3 Wafaie Fawzi of the Harvard University School of Public Health4 led the study. None of the women in the study had H.I.V.5, the virus that causes AIDS.6 The scientists reported earlier that daily multivitamins were a low-cost way to reduce fetal deaths in pregnant women infected with7 H.I.V. The earlier work in Tanzania also found improvement in the mothers in their number of blood cells known as lymphocytes. Lymphocytes increase the body's immunity against infection. The new study in pregnant women who were not infected with the AIDS virus found that multivitamins reduced the risk of low birth weight. Just under eight percent of the babies born to women who took the multivitamins weighed less than2,500 grams. The rate was almost nine and one-half percent in the group of women who received a placebo, an inactive pill, instead of the vitamins. But the vitamins did not do much to reduce the rates of babies being born too early or dying while still a fetus. Still, the researchers say multivitamins should be considered for all pregnant women in developing countries. ͋Gl multivitamin n. Yy~u }6RBR urge v. gR;N _:_pBlfeO pregnant adj. `U[v Y Zv Tanzania n. fWQh<\N^2m diabetes n. |?\u Y?\u Dar es Salaam n. /}e(bYfWQh<\N folate n. Sxv mineral n. wir(e:gv adj. wir(ve:gv fetal adj. lv ΀?Qv lymphocyte n. m]~ހ immunity n. MQuRMQu'` infection n. Og ag Ogu placebo n. [paBRaBRlu inactive adj. e\O(uv pill n. o8N 8NBR fetus n. ΀ ΀?Q lʑ World Health Organization (WHO)NLukSu~~ along withN& Nw New England Journal of MedicineeNw immune adj. MQuv scratchy adj. :Ruv ONSuv runny adj. Am|mv Pittsburgh n. 9SyQ!XVW^ colleague n. TN susceptible adj. fav Oeav catch vt. ag0R trait n. yr(yr'` perceive vt. Sɉ ɉ[t energetic adj. |REQlv |^yqnv easy-going adj. Tv tense adj. '} _v hostile adj. Leav nasal adj. ;v ache n. eޏ~v uu xu sneeze vi. SbUV congestion n. EQ@ mucus n. |m woe n. u |` Y ~p 4Y lʑ 1. warm people likely to keep cold at bay`~PN‰vN Nf`aQ0warm peopleSa/f p_vN `~ؚfvN keep/hold& at bay/f O& pbe NO& cя va` Vdk,gvYgvыR/f `~ؚfvNSaQ N_ b `~ؚfvNS܏yaQ b `~ؚfvNSbaQNCS̑KNY 0 2. staying positiveOcygT Nv`~ 3. expose healthy volunteers to a cold or flu virusOeP^v_?acaQuk bAmauk0exposeSa/f Of2 Ob4N ُ̑expose sb. to sth./f O...c... va`0 4. sunny dispositionPN‰_gv*N'` 5. positive emotional stylePN‰`~W `~ygW 6. ward off_ 2bk 7. scratchy throatUP[u runny noseAm;m 8. susceptible to[& Oeav [fS0R& v 9. as tosQN N ~`N 1. According to a study author, when people with a positive emotional style do get a cold, they may think ___________. A) that their illness is very serious B) that their illness is not so serious C) that they do not get any illness at all D) that the illness they get is not a mild one 2. People with a positive emotional style may have all of the following characteristics EXCEPT ____________. A) happy B) selfish C) easy-going D) energetic 3. Which of the following is NOT one of the characteristics that people with a negative emotional style may have? A) Hostile. B) Unhappy. C) Warm-blooded. D) Tense. 4. How did the researchers test their volunteers? A) By giving everyone nasal drops containing either a cold virus or a particular flu virus. B) By giving everyone a medicine that help lessen the probability of catching cold. C) By giving everyone an injection boosting immune function. D) By investigating everyones characteristics, interests and hobbies. 5. Which of the following items is NOT included in the data that the researchers collected? A) Mucus production. B) Aches and pains. C) Sneezing or congestion. D) Blood test. T{HhN B ,gT{Hheg,{ Nk vQ-N,{NS  S_NNvnx`aQe NN:Nu`v^ N*Y%N͑ 0 B yA0C0D(W,{Nk,{NSGWc0R S gBylc0R NN;ct `~PN‰vN~ NO/f y)R vN0 C yA0B0D_NGW(W,{Nk,{NSc0R Cy p` mn _N N^^\N`~NO=0mgvN@b^ gv'`Nw bowel n.8^(u Ype salad n. rb-NvNyQb܃ Spain n. sYr starch n. m| leucocyte n. }v~ހ lymphocyte n. m]~ހ inflammation n. p puSpMO down-regulation n. N T N Spanish adj. sYrv indicative adj. c:y'`va_'`v:y'`v density n. [^ apoptosis n. ~ހQN~ހv6q{kN simulate vt. !jN !jb resistant adj. gbbRvENv Barcelona n. ]^XWsYr/nS legume n. F F Z pasta n. bߘ cereal n. 8^(u Ype \O:N;N|v 7ir{| digest v. mS intestine n. 8^(u Ype shunt v. O RAm ferment v. O Su immunology n. MQuf[ peripheral adj. hTVvhbv gut n. hypothesis n. f[v GP GP[ inflammatory adj. Spv p'`v lʑ 1. raw potato starch (RPS)*g~R]vWFm| 2. The general down-regulation of leucocytes observed by the Spanish researchers suggests an overall beneficial effect, a generally more healthy body. sYrxvzN@b‰[0RvhQ'` N}v@t4ls^v\O(uasT@w*g~R]vWFm|/fwQ ghQbv gvv\O(uv _N1\/f;`veg􋫎SO/ffReP^0 3. Universitat Autonoma de Barcelona/fsYrN*N\pele---Rl a:N ]^XWꁻl'Yf[ 0ُ/f'Yf[vS T0 4. irritable bowel syndrome (IBS)ǏOe'`~T_ 5. Department of Internal Medicine, Goteborg University, Sweden^txQT_!X'Yf[Qy;Sf[| 6. SCI ( Science Citation Index )yf[_e"}_0Vyf[Oo`xvz@b1961t^RRQHrv_epenc^0 ~`N What a form of potato is the most nutrient to the human body? Potato soup. Potato cake. Potato salad. Hot boiled potato. What does the reduction in leucocyte levels in the body mean? It may mean the reduced levels of inflammation. It may mean somewhere in the body is inflamed. It means that the body is challenged. It means that the body cannot produce leucocytes any more. For what a purpose did the researchers use raw potato starch in their experiment? They wanted to observe how the leucocyte levels reduced in the experimental pigs? They wanted to simulate the effects of a diet high in resistant starch. They wanted to see how much potato an experimental pig ate every day. They wanted to see how much body weight each experimental pig gained in the end. All of the following foods are rich in resistant starch EXCEPT __________. Pasta Grains Legumes Vegetables What a kind of starch is resistant starch after all? It may cause irritable bowel syndrome. It may bring about at least partially inflammatory disorder. It may raise leucocyte and lymphocyte levels in the body. It cannot be digested in the small intestine and ferments in the large intestine. T{HhN 1. C we_4Y,{NS1\  TWF gvNSeP^ N[te*NMQu|~_N gv $\vQ/fTWFrb UQT Vdk(WV*N y-Ng g%{Qv^Cy^\0 2. A ,{ Nk,{ NS  m]~ހ4ls^NO>f:ypu4ls^ NM EevQ[B0C0D N*N yGW Ncknx0 3. B ,{Vk,{NS_(uNxvz~#N]v݋  (W[-NO(u*g~R]vWFm| 1\/f:NN!jb[+TENm|vnߘ@bwv\O(u vQ[A0C0D N*N yezGWl gcS0 4. D ,{Nk,{NSRQNNN[+TENm|vߘT vQ-N1\l gDy ,܃ N[E N,܃_N N/f[+Tm|vߘir0 5. D ,{NkPpe,{NS]~ʑNENm|vyrp N(W\-NmS /fRAm0R'Y (W'Y-NSu 0vQ[ y*N+R͋}(Wwe-NQsǏ FO N/ffENm|v0 When fear takes control of1 the mind A panic attack is a sudden feeling of terror. Usually it does not last long, but it may feel like forever.The cause can be something as normally uneventful as driving over a bridge or flying in an airplane. And it can happen even if the person has driven over many bridges or flown many times before. A fast heartbeat. Sweaty hands. Difficulty breathing.2 A lightheaded feeling. At first a person may have no idea3 what is wrong. But these can all be signs of what is known as panic disorder.4 The first appearance usually is between the ages of18 and 25. In some cases it develops after a tragedy, like the death of a loved one, or some other difficult situation. In the United States, the National Institute of Mental Health5 says more than two million people are affected in any one-year period. The American Psychological Association6 says panic disorder is two times more likely in women than men. And it can last anywhere from a few months to a lifetime. Panic attacks can be dangerous -- for example, if a person is driving at the time. The Chesapeake Bay Bridge in the state of Maryland is so long and so high over the water, it is famous for scaring motorists. There is even a driver assistance program to help people get across. Some people who suffer a panic attack develop a phobia, a deep fear of ever repeating the activity that brought on the attack.7 But experts say panic disorder can be treated. Doctors might suggest anti-anxiety or antidepressant medicines. Talking to a counselor could help a person learn to deal with or avoid a panic attack. There are breathing methods, for example, that might help a person calm down.8 Panic disorder is included among what mental health professionals call anxiety disorders.9 A study published last week reported a link between anxiety disorders and several physical diseases. It says these include thyroid disease, lung and stomach problems, arthritis, migraine headaches and allergic conditions. Researchers at the University of Manitoba in Canada say that in most cases the physical condition followed the anxiety disorder. But, they say, exactly how the two are connected remains unknown. The report in the Archives of Internal Medicine10 came from a German health study of more than4,000 adults. ͋Gl panic n. adj. P`Lav terror n. P`` uneventful adj. s^YeNvs^Qv heartbeat n. _ sweaty adj. YWlv lightheaded adj. 4YfTVpv:@BFʷʤʑʑ~ʷqdqdqdqdqR~#hn0hpc5B*CJKHo(phhn0h[gB*o(phhn0hpcB*o(ph$hn0hpcB*CJKHaJo(ph$hn0h[gB*CJKHaJo(ph$hn0hB*CJKHaJo(ph$hn0ha B*CJKHaJo(ph!hn0ha B*CJKHaJph#hn0ha 5B*CJKHo(ph$h Fha B*CJKHaJo(ph FHLN~?&'bc *ڶڣڣڐڐڐ~mZG$hn0hEB*CJKHaJo(ph$hn0h3u\B*CJKHaJo(ph hn0hb-I5B*CJKHph#hn0hb-I5B*CJKHo(ph$hn0hb-IB*CJKHaJo(ph$hn0h B*CJKHaJo(ph!hn0h<3B*CJKHaJph$hn0hpcB*CJKHaJo(ph$hn0h<3B*CJKHaJo(ph$hn0h*\lB*CJKHaJo(phHs?'fc4 $WD^`$gdkQ $d1$a$gdkQ WDd`gdkQJWDj^J`gdkQgdkQHWD8^`HgdkQh^hgdkQ*0H2 4 !!!T!!ڴ{{{{hhhU$hn0ho"B*CJKHaJo(ph$hn0h=B*CJKHaJo(ph$hn0h jB*CJKHaJo(ph$hn0h:TB*CJKHaJo(ph$hn0hb-IB*CJKHaJo(ph$hn0h!YB*CJKHaJo(ph$hn0h<3B*CJKHaJo(ph$hn0hEB*CJKHaJo(ph$hn0h3u\B*CJKHaJo(ph !!!!!n"$&`()~++++++,@,`,, WD`gd9d,1$WD`gdkQ$`d,1$WD``a$gdkQgdkQ$WD^`$gdX;$WD^`$gdkQ!!!!!!!""####$($)$*$N$V$W$k$w$$ϾyhWFh!hpGh*\lB*CJKHaJph hpGh*\lB*CJKH\ph hn0h*\lB*CJKH\ph$hn0hI!fB*CJKHaJo(phhdB*CJKHaJph#hn0h7B*H*KHaJo(ph#hrlh7B* H*KHaJo(ph!hrlh*\lB* CJKHaJph!hX;hrlB*CJKHaJphho"B*CJKHaJph!hn0h*\lB*CJKHaJph$$|((((v*x*<+>+~+++++++++,,*,>,X,^,~,,,ݻݩݚwfwfwfwfwfwWwFW hPhB*KHaJo(phhPhB*KHaJph hPhyB*KHaJo(ph hPh;B*KHaJo(ph#hn0h;5B*CJKHo(phh&5B*CJKHo(ph#hn0h7B*H*KHaJo(ph hn0h7B*H*KHaJph hn0h*\lB*CJKH\ph!hn0h*\lB*CJKHaJph!hn0hI!fB*CJKHaJph,,,,,,,,,,,- --0-F-d-~----------- .....4.ϾϾϾϾϭ}kX$hn0hB*CJKHaJo(ph#hn0h;5B*CJKHo(ph$hn0h;B*CJKHaJo(phhB*KHaJo(phhPh;B*KHaJph hPh2B*KHaJo(ph hPh;B*KHaJo(ph hPhyB*KHaJo(phhPhB*KHaJph hPhB*KHaJo(ph!,,,-H-----...@...$///>0}00$111 2JWDj^J`gdkQh^hgdkQ & FgdkQgdkQ WD`gd94.6.<.@.f.r.........// /"/$/Ǵڡ~lYD/D(hn0h{ B*CJKHQJaJo(ph(hn0hB*CJKHQJaJo(ph%hn0hB*CJKHQJaJph#hn0h{ B*CJKH\o(ph#hn0hB*CJKH\o(ph hn0hB*CJKH\ph$hn0h{ B*CJKHaJo(ph$hn0hB*CJKHaJo(ph$hn0h;B*CJKHaJo(ph$hn0h*B*CJKHaJo(ph$hn0h2B*CJKHaJo(ph$///////=0>0001224 444J4N444ʸllZIlll hn0h^5B*CJKHph#hn0h^5B*CJKHo(ph$hn0h^B*CJKHaJo(ph$hn0h*\lB*CJKHaJo(ph$hn0hlIB*CJKHaJo(ph$hn0hB*CJKHaJo(ph#hn0h5B*CJKHo(ph!hn0h*\lB*CJKHaJph$hn0h{ B*CJKHaJo(ph!hn0hB*CJKHaJph 2_222Q333334L44>554667777<7F7 $d,1$a$gdkQgdkQ & FgdkQ $d1$a$gdkQJWDj^J`gdkQh^hgdkQ4<5@55552666R6Z6j666666677777:7<7ǶǣڣځseRBh*\l5B*CJKHaJph$hX;h*\l5B*CJKHaJphh FB*CJKHaJphh*\lB*CJKHaJph!hn0h*\lB*CJKHaJph!hn0hr5B*CJKHaJph$hn0hr5B*CJKHaJo(ph!hn0h@B*CJKHaJph$hn0h@B*CJKHaJo(ph$hn0h^B*CJKHaJo(ph$hn0h gB*CJKHaJo(ph<7F7777D8E8F8888899::Y;Z;<<Z=[===??J@K@BB޻rr`rN#hn0hk5B*CJKHo(ph#hn0hkB*H*KHaJo(ph$hn0hkB*CJKHaJo(ph!hn0hkB*CJKHaJph#hn0h5B*H*KHaJo(ph$hn0h5B*CJKHaJo(ph!hn0h*\lB*CJKHaJph#hrlh5B* H*KHaJo(ph!hrlh*\lB* CJKHaJph hrlhrlB*KHaJo(phF778: <]=K@AABAB:B\BxBBBBB(CXCrCCDD D WD`gdo>CgdkQd,1$WD`gdkQd1$WD]`gdkQBB B$B&B8B:BNBPBTBVBZBrBvBBBBBBBBBBBCCC&CNCVClCpCrCtC~CCCCCC DDDD D(Dͼޫ͚އu#hn0hc 5B*CJKHo(ph$hn0hc B*CJKHaJo(ph hPhB*KHaJo(ph hPhCBFB*KHaJo(ph hPh*\lB*KHaJo(ph hPh B*KHaJo(ph hPhc B*KHaJo(ph hPhkB*KHaJo(ph-(DbDfD~DDDDDDDDDD EEE E6E8EEEEEEE*F6FnF|FFFFFFFGοή߮ο}l[ll[l hPh*\lB*KHaJo(ph hPhC-B*KHaJo(ph hPhOtHB*KHaJo(phhPhQNB*KHaJph hPhQNB*KHaJo(ph hPhc B*KHaJo(phhPhCBFB*KHaJph hPhCBFB*KHaJo(ph hPhln0B*KHaJo(phhPhln0B*KHaJph# DDDEEE.FFFGZG\GdGGG H&H/HaHHHI0IgI$IfgdkQl WD`gdkQgdkQ\WD8^`\gdkQGGGGFGXGZG\GbGGGGGGG HH&H.H/Hﾫr^KrKrKrK:!hn0h-B*CJKHaJph$hn0h-B*CJKHaJo(ph'hn0h>*B*CJOJQJo(ph'hn0h->*B*CJOJQJo(ph$hn0hln0B*CJKHaJo(ph#hn0hln05B*CJKHo(ph$hn0h*\lB*CJKHaJo(ph hPhln0B*KHaJo(ph hPhoB*KHaJo(phhPhln0B*KHaJph hPhC-B*KHaJo(ph/HpHHH&I/I>IGIYIgIiIIIIIIJJJ.JJJJK(K˺˺˺p\p\\I\$hn0hB*CJKHaJo(ph'hn0hF>*B*CJOJQJo(ph!hn0hFB*CJKHaJph$hn0hFB*CJKHaJo(ph$hn0h +B*CJKHaJo(ph$hn0h-B*CJOJQJo(ph hn0h +B*KHaJo(phhn0h +B*KHaJph$hn0h +B*OJQJaJo(ph$hn0h-B*OJQJaJo(phgIhIiII.JJ(K*KKLnQ;$IfWDj^;`gdkQl$IfgdkQlHWD8^`HgdkQgdkQikd$$Ifl:Se t0644 la (K*K,K.KKKKKLL|L~LLLLLLMMnMpMrMtMMMʷʷʷʷs```M$hn0h8B*CJOJQJo(ph$hn0h8B*OJQJaJo(ph hn0h*LB*KHaJo(phhn0h*LB*KHaJph!hn0hFB*CJKHaJph$hn0hFB*OJQJaJo(ph$hn0h*LB*OJQJaJo(phhjkB*OJQJaJo(ph$hn0hF1B*OJQJaJo(ph$hn0hAPxB*CJKHaJo(phLzLLpMMMMMjNNOxsg___ & F gdkQ $d1$a$gdkQgdkQikdR$$Iflh t0644 la;$IfWDj^;`gdkQl MMMMMN NhNjNnNNNNNN@O~OOOOOʷm\mmII6I$hn0h,c4B*CJKHaJo(ph$hn0hqB*CJKHaJo(ph!hn0h?B*CJKHaJph$hn0h?B*CJKHaJo(ph$hn0hFB*CJKHaJo(ph!hn0h*K+B*CJKHaJph$hn0h*K+B*CJKHaJo(ph$hn0h8B*CJKHaJo(ph hn0h85B*CJKHph#hn0h85B*CJKHo(ph$hn0hFB*CJOJQJo(phOOOOP PPpPPPPPRTVXYYZ,ZDZfZZ[V[v[[[ WD`gdXd,1$WD`gdkQ$a$gd?;gdkQ & F gdkQjTkTUUqWrWXXPYQYYZZ$Z*Z,Z>ZBZDZXZ^ZdZfZܸܥܸܖufYufJ>ufuhXB*aJo(phhPh*\lB*aJo(phhPh*\lB*aJphhPhBx7B*aJo(phhPhA|B*aJo(ph#hn0hA|5B*CJKHo(phh&5B*CJKHo(ph$hn0hwB*CJKHaJo(ph#hn0hA|B*H*KHaJo(ph#hn0h0aB*H*KHaJo(ph!hn0h*\lB*CJKHaJph#hn0h+B*H*KHaJo(phfZzZ~ZZZZ[[8[:[D[H[J[T[V[f[p[t[v[[[[[[[[[[[\ӱygZMhn0h2B*o(phhn0hc$7B*o(ph#hn0h25B*CJKHo(ph#hn0h9W5B*CJKHo(phhn0h9WB*o(phhXB*aJo(phhPh9WB*aJph hPhBx7B*KHaJo(ph hPh9WB*KHaJo(phhPhBx7B*aJo(phhPh9WB*aJo(phhPhwB*aJo(ph[[[(\T\6^^__D`F`N````6aDaaabKbb$IfgdkQlJWDj^J`gdkQHWD8^`HgdH} & F gdkQgdkQ\$\&\(\4\F\H\N\R\T\X\Z\b\ ]]L]]]]]]]]ȶm]mJ9m!hn0h)$B*CJKHaJph$hn0h7pB*CJKHaJo(phhH}B*CJKHaJo(ph$hn0h2B*CJKHaJo(ph$hn0h)$B*CJKHaJo(ph!hn0h2B*CJKHaJph#hn0hBx7B*CJKH\o(ph#hn0h2B*CJKH\o(ph hn0h2B*CJKH\phhn0h7pB*o(phhn0h2B*o(phhn0hBx7B*o(ph]] ^^4^6^<^z^^^^6_8_T_X_\_^_d_|_~_____ڼګyjYHjH hThG+qB*KHaJo(ph hTh2B*KHaJo(phhTh2B*KHaJph hTh2B*KH\aJph#hTh2B*KH\aJo(phhTh2B*aJo(ph hTh)$B*KHaJo(phhn0h2B*o(ph!hn0h2B*CJKHaJph$hn0h)$B*CJKHaJo(ph$hn0h2B*CJKHaJo(ph_____ `,`B`D`F`L`n``````a6aBaDaпВmYmYmYmYF5!hn0hc$7B*CJKHaJph$hn0hc$7B*CJKHaJo(ph'hn0hAPx>*B*CJOJQJo(ph$hn0hAPxB*CJKHaJo(ph#hn0hAPx5B*CJKHo(phhn0hAPxB*o(ph hTh2B*KHaJo(phhTh2B*KHaJph hTh7pB*KHaJo(phhTh2B*aJo(ph hThG+qB*KHaJo(phhThG+qB*KHaJphDaFaaa"b:b*B*CJphhn0hHuaB*aJo(phhn0hHuaB*aJphhn0hHua>*B*CJph!hn0hHuaB*CJKHaJph$hn0hcUaB*CJKHaJo(ph!hn0hcUaB*CJKHaJph!hn0hoB*CJKHaJphcccccccccccccc7d8ddd˻훋zkZM@M@1hn0hrB*aJo(phhn0hrB*aJphhn0hc$7B*aJph hn0hc$7B*KHaJo(phhn0hCB*aJo(ph!hn0hrB*CJKHaJphhn0hr>*B*CJo(phhn0hr>*B*CJph!hn0hCB*CJKHaJphhn0hC>*B*CJo(phhn0hC>*B*CJph$hn0hCB*CJKHaJo(ph$hn0hrB*CJKHaJo(phc8ddde[eeeeffxsgW$ & Fd1$a$gdkQ $d1$a$gdkQgdkQikd)$$Ifl h t0644 la;$IfWDj^;`gdkQl dddeeeffff8f>fffff ggLgPgTg^gdgxg~g|kkZ|II|II hn0hhQB*KHaJo(ph hn0hA|B*KHaJo(ph hn0hG+qB*KHaJo(phhg~B*KHaJo(ph hn0hcUaB*KHaJo(ph#hn0h@5B*CJKHo(ph$hn0hAPxB*CJKHaJo(ph$hn0hc$7B*CJOJQJo(phh*h@B*aJo(phhn0hrB*aJo(phhn0h@B*aJo(phfNgg8hh iiiijjj"jjlZno~qwsxstd,1$WD`gdkQ$`d,1$WD``a$gdkQ $1$@&a$gdkQgdkQ$ & Fd1$a$gdkQ~ggggggh6h:h>h\hnhphhhhhhiiiiBivi|iiiiiiiiiiijjjjп޿޿п޿пޮЮޮޮޤzjh*\l5B*CJKHaJph$hX;h*\l5B*CJKHaJphhn0hUcB*o(phhUcB*o(phhA|B*o(ph hn0hB*KHaJo(ph hn0h.kB*KHaJo(phhg~B*KHaJo(ph hn0hcUaB*KHaJo(ph hn0h2B*KHaJo(ph&jjj j"jjj l!lwlllmmAoBoooqprp{q|q s!swstto`N#hn0h'5B*CJKHo(phh&5B*CJKHo(ph h$wh'B*KHaJo(phh$wh'B*KHaJph#h$wh'B*H*KHaJo(phh$wh*\lB*KHaJph h$wh*\lB*KH\aJph!h,h*\lB* CJKHaJphh,h,B*KHaJph h,h,B*KHaJo(phh,B*KHaJo(pht$t&t,t4t6tJtNtPtjtpttttttttttο}l}ZlD+h*4h*4B*H*KHOJQJaJo(ph#h*4hJa5B*KHaJo(ph h*4h*4B*KHaJo(ph h*4hJaB*KHaJo(phh^B*CJKHaJo(phhJaB*CJKHaJo(ph h*4h^B*KHaJo(phh*4h*\lB*KHaJphh'B*CJKHaJo(ph!h'h*\lB*CJKHaJph h'h*\lB*CJKH\pht6tPtptttt0uVuuuuuv6vVvvvv w4wNwzwwwwwgdkQ WD`gd>ID WD`gd>IDttttttt u.u0uFuTuVujulu|uuuuuuuuuuuuuu˻˻˻ziXiXiXi h$wh B*KHaJo(ph h$whJaB*KHaJo(phh h B*KHaJphh B*CJKHaJo(ph h hJaB*KHaJo(ph h h B*KHaJo(phhJaB*CJKHaJo(ph h*4hJaB*KHaJo(ph h*4h*4B*KHaJo(ph#h*4h*4B*H*KHaJo(phuvvv$v4v6vLvTvVvdvlvxvzv|v~vvvvvЮr^J6& juh$wh&B*KHaJo(ph& jjh$wh&B*KHaJo(ph& jh$wh&B*KHaJo(ph& jsh$wh&B*KHaJo(ph& jih$wh&B*KHaJo(ph& jmh$wh&B*KHaJo(ph h$wh$wB*KHaJo(ph h$whKB*KHaJo(ph h$wh B*KHaJo(ph h$whJaB*KHaJo(phh>IDB*KHaJo(phvvvvvvvvvw w ww&w2wHwLwpwxwwwwwwwwwǶǶǶǶǨǶǶǶǶǖtfVh' B*CJKHaJo(phhKB*CJKHaJphhKB*CJKHaJo(ph#hn0hK5B*CJKHo(ph#hJahK5B*CJKHo(phh>IDB*KHaJo(ph h$wh$wB*KHaJo(ph h$whKB*KHaJo(ph& jsh$wh&B*KHaJo(ph& jh$wh&B*KHaJo(phwwwwxZx\xdxtxxxyyyyzz&z0z:ztzzzzzzݿݞݞ~m_N~D~NhY B*o(ph!hn0hY B*CJKHaJphhB*CJKHaJph!hn0hB*CJKHaJphhY B*CJKHaJo(phhB*CJKHaJo(ph!hn0hKB*CJKHaJphh*\lB*CJKHaJo(phh' B*CJKHaJo(phhKB*CJKHaJphhKB*CJKHaJo(ph$hn0h*\lB*CJKHaJo(phw\xx2zzz{{{|P|||| }R}}}}7~k~~~`gdkQ WD`gdkQ & FgdkQyVDFWD^y`gdkQgdkQHWD8^`HgdkQzzzz<{L{P{d{t{|{{{{{||5}7}}}}6~7~̼̼ݼyogoZoPBPoh-@ehZCJOJQJo(hB*o(phh*\lhZCJKHaJhZB*phhZB*o(ph$hn0hZB*CJKHaJo(ph#hn0hZ5B*CJKHo(phhKB*CJKHaJo(phhY B*CJKHaJphhB*CJKHaJo(ph!hn0hY B*CJKHaJphhY B*CJKHaJo(ph$hKhKB*CJKHaJo(ph7~L~j~k~  rz}~Ā؀ȁʁஞzjj\jJj:hDs+B*CJKHaJo(ph#hn0hQ|5B*CJKHo(phhQ|B*CJKHaJphhQ|B*CJKHaJo(ph$hNahKB*CJKHaJo(ph!hn0hQ|B*CJKHaJphhn0hQ|>*B*CJo(phhn0hQ|>*B*CJph$hZhNaB*CJKHaJo(phhKB*CJKHaJo(phhNaB*CJKHaJo(phhB*CJKHaJo(ph~ ~܀$RNJNP$d,1$WDX`a$gdkQ $d1$a$gdkQgdkQHWD8^`HgdkQ`gdkQʁҁԁ@BPR\^‚NXZHJLNPqcUh,B*CJKHaJphh B*CJKHaJphh=X6B*KHaJo(ph h$wh=X6B*KHaJo(phh=X6B*CJKHaJo(phhP-B*CJKHaJo(phhDs+B*CJKHaJo(phh B*CJKHaJo(phhKB*CJKHaJo(phhQ|B*CJKHaJo(phh}4B*CJKHaJo(ph PJLԇ$% MN*+ݾݭݾݾݾݾ݊ݾ{iWF hw1h*\lB*KH\aJph#hw1hw1B*KH\aJo(ph#hn0h5B*CJKHo(phh&5B*CJKHo(ph#h$whB*H*KHaJo(ph!hh*\lB*CJKHaJph hh*\lB*CJKH\phhB*H*KHaJo(phhB*CJKHaJo(ph!hn0h*\lB*CJKHaJph!h,h*\lB* CJKHaJph,ʎ JrΏ8^ސ <>F WD`gdDs+ VD^gdDs+gdkQd,1$WD`gdkQĎƎȎʎڎ8HbpƏ̏*6T\vʐܐ 2:>ұң{hDs+B*KHaJphhN@{B*KHaJo(phhI)B*KHaJo(phhw1B*KHaJo(ph$h9oh*\lB*CJKHaJo(phh9oB*KHaJo(phh8XB*KHaJo(phhw1h*\lB*KHaJph hw1hw1B*KHaJo(ph*>FxʒΒВؒ,BD̼̬ܜ{j{ܜW̜G̜h*\lB*CJKHaJo(ph$hn0h*\lB*CJKHaJo(ph hThTB*KHaJo(ph$hn0hTB*CJKHaJo(phhYB*CJKHaJphhYB*CJKHaJo(phhw1B*CJKHaJo(phhI)B*CJKHaJo(phhTB*CJKHaJo(ph!hn0hTB*CJKHaJph#hn0hw15B*CJKHo(phFВD&`bj@`9Yn5e`gdkQHWD8^`HgdkQNUDaVDWDd]^N`gdkQgdkQ & FgdkQ$&RZ\^`bhj>@^`489mZJJJ:J:J:h*B*CJKHaJo(phh!B*CJKHaJo(ph$hn0hTB*CJKHaJo(ph#hn0hT5B*CJKHo(ph$hn0hYB*CJKHaJo(phh*\lB*CJKHaJo(phhYB*CJKHaJphhYB*CJKHaJo(phhTB*CJKHaJo(ph#h7OhTB*KH\aJo(phh7OB*KHaJo(phh7OB*CJKHaJo(ph9XY>Ze !klϙЯ~k~~[~[I[#hn0hH5B*CJKHo(phhHB*CJKHaJo(ph$hFhTB*CJKHaJo(phhJ/NB*CJKHaJo(ph!hn0hFB*CJKHaJphhFB*CJKHaJo(ph$h*hvc!B*CJKHaJo(phhvc!B*CJKHaJphhvc!B*CJKHaJo(phhTB*CJKHaJo(phh*B*CJKHaJo(phe!VęϙЙЛPL$xd1$WD`xa$gdkQ $d1$a$gdkQ`gdkQgdkQHWD8^`HgdkQ.4zКҚԚؚ֚ښ"$(246>@VXrtΛڛܛ.02468NPZ\ЃЃЃЃЃЃsh;B*CJKHaJo(phhfB*CJKHaJo(phhVC)B*KHaJo(phhw1hVC)B*KHaJphhTB*CJKHaJo(phhVC)B*CJKHaJo(phhHB*CJKHaJo(phhYB*CJKHaJo(phhUcB*CJKHaJo(ph-ʜΜԜ؜ܜHJLlndeƞǞ9:LM+,´tbtbtbtTtbtbtbthwFB*KHaJo(ph#hwFhwFB*H*KHaJo(phhwFh*\lB*KHaJph#h,hwFB* H*KHaJo(ph!h,h*\lB* CJKHaJphh,B*CJKHaJphhTB*CJKHaJphhTB*CJKHaJo(phh1 QB*CJKHaJphh;B*CJKHaJo(phhHB*CJKHaJo(phLǞ.: X֥إ<T~ڦ*Jz̧2h WD`gdDs+gdkQ WD`gdkQd,1$WD`gdkQӡԡ WX&ԥ֥إ:NRr|μμέ΋zhZL>LZLZLZh*\lB*KHaJo(phh#'B*KHaJo(phh;jAB*KHaJo(ph#hn0h;jA5B*CJKHo(ph hWhWB*KHaJo(ph hjh*\lB*KHaJo(ph hWh*\lB*KHaJo(phhwFhWB*KHaJph#hwFhwFB*H*KHaJo(phhwFh*\lB*KHaJph#hwFh*\l5B*KH\aJph hwFh*\lB*KH\aJphΦئ(@Hfxʧ 0PfШ.4RVjn~䛉{hWB*KHaJo(ph#hn0hW5B*CJKHo(ph h;jAh;jAB*KHaJo(phhNfB*KHaJo(phhUB*KHaJo(phh\B*KHaJo(phhDs+B*KHaJo(phh;jAB*KHaJo(phh#'B*KHaJo(ph/hШ6XpZ^Ddĭƭ WDd`gdkQ\WD8^`\gdkQ$\d1$WD8^`\a$gdkQgdkQ WD`gdDs+*,LNV`dprvx >VXZbn«ګǻǻ՟䓟xj^xPh?HB*KHaJo(phhjB*KHaJphh;jAB*KHaJo(phhwFhjB*KHaJphh;aB*KHaJphhNfB*KHaJphh;aB*KHaJo(phh@p/B*KHaJo(phhWB*KHaJphhWB*KHaJo(phhWhWB*KHaJphhNfB*KHaJo(phhjB*KHaJo(phګ$<\fҬ8@BDZbl­ƭʻʻʻʻʋymmʻh?HB*KHaJph#hwFhj5B*KH\aJph hwFhjB*KH\aJphh;jAB*KHaJo(ph hjh;jAB*KHaJo(phhwFhjB*KHaJphhjB*KHaJo(phhjB*KHaJphh?HB*KHaJo(phhcB*KHaJo(ph'ƭ̭έHQ^_wx}k~LN\b̢̢̢̰̰̾̔ziWzIh?HB*KHaJo(ph#hn0hK5B*CJKHo(ph hkh5B*KHaJo(phhKB*KHaJo(phh5B*KHaJphh5B*KHaJo(phh AB*KHaJo(phh;jAB*KHaJo(phh4D,B*KHaJo(phhkB*KHaJo(ph$hn0hkB*CJKHaJo(ph#hn0hk5B*CJKHo(phƭέ_ۮ y 1BXgT~$ VD^gdkQ`gdkQ\WD8^`\gdkQgdkQ$LN\.JLN[2 WD`gd\wgdkQ 1$WD`gdm$H1$@&WD,`Ha$gdkQgdd & FgdkQ $d1$a$gdkQ\WD8^`\gdkQ³Ƴȳʳ̳γг,.248:<>@B\^46HJLN京th,h*\lB* CJKHph!h,h*\lB* CJKHaJphh,B*KHaJphhdB*KHaJphh*\lB*KHaJo(phhlB*KHaJo(phhcB*KHaJo(phh;jAB*KHaJo(phhKB*KHaJo(phhA$B*KHaJo(ph,stֹ׹عٹ;QFHJ02X߰߰߰{qgYhSB*KHaJo(phh*\lB*o(phhaB*o(phhOB*o(phhmB*o(ph#hn0hO5B*CJKHo(phh&5B*CJKHo(ph!hn0hIw8B*CJKHaJphhIw8B*CJKHaJphhIw8B*CJKHaJo(phhIw8B*H*KHaJo(ph!hn0h*\lB*CJKHaJph2Xx"V @f:T~$V WD`gd\wXvx BTVv| $>@Zdfz8NRn| "@PͿͮͮͿﮝ h`ShwB*KHaJo(ph h`ShoB*KHaJo(phhmB*KHaJo(ph h`ShOB*KHaJo(ph h`Sh*\lB*KHaJo(ph h`ShaB*KHaJo(ph;PTz24<x̼{jYH9jh!2mh,"B*KHaJph h!2mh,"B*KHaJo(ph h!2mhOB*KHaJo(ph h!2mh\,rB*KHaJo(phh\,rB*CJKHaJo(phhOB*CJKHaJo(phh,CB*CJKHaJo(ph!hn0h,"B*CJKHaJphh,"B*CJKHaJo(ph#hn0ho5B*CJKHo(ph h`ShoB*KHaJo(ph h`Sh,CB*KHaJo(ph4&4NhCr%w & FgdkQ & FgdkQ\WD8^`\gdkQHWD8^`HgdkQgdkQ $&.4j24ϾﮝzjXE5j5h0 B*CJKHaJo(ph$hn0h0 B*CJKHaJo(ph#hn0h0 5B*CJKHo(phhOB*CJKHaJo(ph$h,"hOB*CJKHaJo(phh\,rB*CJKHaJo(ph!hn0h,"B*CJKHaJphh,"B*CJKHaJo(ph h!2mh\,rB*KHaJo(phh!2mh,"B*KHaJph h!2mh,"B*KHaJo(ph h!2mhOB*KHaJo(phZ h2DОООЎЎЎЎ~ЎЎЎЎ~~~nh!2mB*CJKHaJo(phh]6B*CJKHaJo(phhXUB*CJKHaJo(phhi{B*CJKHaJo(ph#hn0h2)$5B*CJKHo(phhOB*CJKHaJo(phh2)$B*CJKHaJo(phhJB*CJKHaJo(phhLB*CJKHaJo(ph(VZ 42$xd,1$WD`xa$gdkQHWD8^`HgdkQ $d1$a$gdkQgdkQ & FgdkQ & FgdkQ2+56 789rst̸̖wfWFwWFWFWFW!hn0hB*CJKHaJphhB*H*KHaJo(ph!hh*\lB*CJKHaJph hh*\lB*CJKH\phhB*CJKHaJph!hn0h*\lB*CJKHaJph!h\whB* CJKHaJph'h\whB* CJH*KHaJo(ph!h\wh*\lB* CJKHaJph$hn0h&B*CJKHaJo(phh*\lB*CJKHaJo(ph25^8l <j 2~ WD`gd"jgdkQd,1$WDd`gdkQd,1$WD`gd\w denr26X\sdPdAdhskB*KH\aJo(ph&hskhw5B*KH\aJo(phh::B*KH\aJo(ph&hskhsk5B*KH\aJo(ph#hskhskB*KH\aJo(ph#hn0hw5B*CJKHo(ph$hn0hdB*CJKHaJo(phh*\lB*CJKHaJo(ph!hn0hB*CJKHaJphhB*H*KHaJo(ph!hn0h*\lB*CJKHaJph\`bdj":PRV~m^M^Mhu:B*CJKH\o(ph#hu:hskB*CJKH\o(phh*B*CJKHaJph#hu:hu:B*CJKH\o(ph#hskhskB*KH\aJo(phh*B*CJKHaJo(ph!hn0hu:B*CJKHaJphhu:B*CJKHaJo(phhu:B*KH\aJo(ph hu:hskB*KHaJo(phh*B*KHaJo(phhu:hu:B*KHaJph $(lx̻މxgVxgGgh&B*KH\aJo(ph hw5B*CJKH\o(ph!hn0hbBB*CJKHaJph hbB5B*CJKH\o(ph#hbBhbBB*CJKH\o(phhbBB*CJKHaJo(phhu:B*CJKHaJo(ph!hn0hu:B*CJKHaJph#hu:hu:B*CJKH\o(ph#hu:hwB*CJKH\o(phh*B*CJKHaJo(ph $*d~>HLRT\ѿѮўѮ~Ѯ~lY$hn0hbBB*CJKHaJo(ph#hn0hbB5B*CJKHo(phhu:B*CJKHaJo(phh B*CJKHaJo(phh*\lB*CJKHaJo(ph!hn0hbBB*CJKHaJph#h&hwB*KH\aJo(phhbBB*CJKHaJo(phh&B*KH\aJo(phh&B*CJKHaJo(ph\ 2Slmpp`pM;#hn0hA&U5B*CJKHo(ph$h;hB*CJKHaJo(phh6sB*CJKHaJo(phhB*CJKHaJo(phhacB*CJKHaJo(phhGpB*CJKHaJo(phhbBB*CJKHaJo(phh;B*CJKHaJo(ph$hbBhu:B*CJKHaJo(phh;B*CJKHo(phhbBB*CJKHo(ph hbBhbBB*CJKHo(phEZo;W2a2Kmn(* $d1$a$gdkQgdkQHWD8^`HgdkQ`gdkQ8:@B^z &(6 (8J~ ~h>B*CJKHaJo(ph!hn0hA&UB*CJKHaJphhA&UB*CJKHaJphhbBB*CJKHaJo(phh^>B*CJKHaJo(phh B*CJKHaJo(phhA&UB*CJKHaJo(phhUB*CJKHaJo(ph0=>?%&89#$Ut]^}̺̩||m|||m|]]mha3B*CJKHaJo(phha3B*H*KHaJo(phha3B*CJKHaJphh$B*CJKHaJo(phh$B*H*KHaJo(ph!hn0h*\lB*CJKHaJph#h,hEB* H*KHaJo(ph!h,h*\lB* CJKHaJphhbBB*CJKHaJo(ph$hA&UhbBB*CJKHaJo(ph$?4f6ZJ WD`gd 1$WDd`gdkQ 1$WD`gd$1$@&WDd`a$gdkQgdkQVu&24R\dzi[JJ h#0hB*KHaJo(phhB*KHaJo(ph h#0h*\lB*KHaJo(ph h#0hnAB*KHaJo(ph h#0hB*KHaJo(ph#hn0h5B*CJKHo(ph$hn0hdB*CJKHaJo(phh*\lB*CJKHaJo(phha3B*CJKHaJphha3B*H*KHaJo(ph!hn0h*\lB*CJKHaJph,4<RXZpv~4Hx0^`οήή߮߮߮߮߮߮߮߮|k|k|k| h<hI B*KHaJo(ph h<hB*KHaJo(ph#hn0h5B*CJKHo(phh#0hB*KHaJph h#0hB*KHaJo(phh#0hB*KHaJph h#0hB*KHaJo(ph h#0hB*KHaJo(phh#0hB*KHaJph)br0pz ( .A\`gdkQHWD8^`HgdkQ\WD8^`\gdkQgdkQ`bj &02JfnϾpbR?Rppb$hn0hB*CJKHaJo(phhB*CJKHaJo(phhB*CJKHaJph!hn0hB*CJKHaJphh<B*CJKHaJphh<B*CJKHaJo(phhI B*CJKHaJo(phh<hI B*KHaJph h<hI B*KHaJo(phh<hB*KHaJph h<hB*KHaJo(ph h<hB*KHaJo(ph8:Z^,.Lprz,.𝍝}}}j}Z}}h3B*CJKHaJo(ph$hh*\lB*CJKHaJo(phhB*CJKHaJo(phh+B*CJKHaJo(ph!hn0h+B*CJKHaJph$hn0h*\lB*CJKHaJo(phh<B*CJKHaJo(phh<B*CJKHaJph!hn0hB*CJKHaJphhB*CJKHaJo(ph!.08NTV^`hjlxPTVhr 0246ппп߿п߿ппߟ|& jhCh`B*KHaJo(phhCh`B*KHaJph hCh`B*KHaJo(phhCh3B*KHaJph hCh3B*KHaJo(phhCh+B*KHaJph hCh+B*KHaJo(phh*\lB*CJKHaJo(ph)68:<>@BDFHL\İt`L;* hCh`B*KHaJo(ph hCh3B*KHaJo(ph& jhCh`B*KHaJo(ph& jmhCh`B*KHaJo(ph& jihCh`B*KHaJo(ph& jahCh`B*KHaJo(ph& jhhCh`B*KHaJo(ph& jshCh`B*KHaJo(ph& jthCh`B*KHaJo(ph& jlhCh`B*KHaJo(ph& jQhCh`B*KHaJo(ph \nr &( b߾yyyfyyVyVFVFh?(B*CJKHaJo(phhdB*CJKHaJo(ph$h?h?B*CJKHaJo(phh?B*CJKHaJo(phh`B*CJKHaJo(ph$hn0h`B*CJKHaJo(ph#hn0h`5B*CJKHo(phh+B*CJKHaJo(ph hChCB*KHaJo(ph hCh`B*KHaJo(phhCh`B*KHaJph ; :   ^  < > L   2   $d1$a$gdkQ VD^gdkQHWD8^`HgdkQ`gdkQ      < > L Z          4 6 L N j      {{mm{{{]hi \B*CJKHaJo(phhgB*CJKHaJphhvB*CJKHaJo(phh3~ B*CJKHaJo(ph#hn0hg5B*CJKHo(ph$hghgB*CJKHaJo(phhgB*CJKHaJo(phh?(B*CJKHaJo(ph!hn0h?(B*CJKHaJphh?(B*CJKHaJph   $ , 0 2 < f r      ࿱࿱Гp_N>NhX;h8B* H*aJo(ph!hX;h*\lB* CJKHaJph hX;hX;B*KHaJo(phh*\l5B*CJKHaJph$hX;h*\l5B*CJKHaJphh%NbB*CJKHaJo(phhf}B*KHaJo(phhi \B*KHaJo(ph hChi \B*KHaJo(phhgB*CJKHaJo(phhi \B*CJKHaJo(phh }B*CJKHaJo(ph9d:^NvUDaVDWD,]^N`vgd"K NUDaVDWDd]^N`gdkQd,1$WD`gdkQ$xd,1$WD`xa$gdkQgdkQHWD8^`HgdkQ<@"#Zr4bd;ͮ;ͮͮ;͋͋|jZKh%eB*KH\aJo(phh*\lB*CJKHaJo(ph#hn0h85B*CJKHo(phhd5B*CJKHo(phhmB*CJKHaJo(ph$hn0h*\lB*CJKHaJo(phhB*CJKHaJo(phh8B*H*aJo(phU!hn0h*\lB*CJKHaJph!h8h*\lB*CJKHaJph h8h*\lB*CJKH\phrest.2 The heart stops pumping blood. The person stops breathing. Without lifesaving measures, the brain starts to die within four to six minutes. CPR combines breathing into the victim's mouth and repeated presses on the chest. __________(1)__________ However, a new Japanese study questions the usefulness of mouth-to-mouth breathing. The study was published in the British medical magazine, The Lancet.3 Doctors in Tokyo led the research. It examined more than four thousand people who had suffered cardiac arrest. In all the cases, witnesses saw the event happen. More than one thousand of the victims received some kind of medical assistance from witnesses. Seven hundred and twelve received CPR. Four hundred and thirty-nine received chest presses only. __________(2)________ The researchers say any kind of CPR improved chances of the patient's survival. But, they said those people treated with only chest presses suffered less brain damage. Twenty-two percent survived with good brain ability. __________(3)__________ The American Heart Association4 changed its guidelines for CPR chest presses in 2005. __________(4)__________ Gordon Ewy is a heart doctor at the University of Arizona College of Medicine in Tucson. He wrote a report that appeared with the study. Doctor Ewy thinks the CPR guidelines should be changed again. He said the heart association should remove rescue breaths from the guidelines. He argues that more witnesses to cardiac arrests would provide treatment if rescue breaths are not a part of CPR. He says this would save lives. __________(5)__________ Cardiac arrest kills more than 300,000 people in the United States every year. The American Heart Association says about ninety-five percent of victims die before they get to a medical center. ͋Gl chest n. ^ compression n. SRS pump n. l vt. SQ lifesaving adj. Qeuv n. Qeul press vt. n. S c Tokyo n. NNe,g witness n. vQN v. \O rescue vt. n. Qec %Qe guildline n. e QR lʑ 1 CPR (cardiopulmanory resuscitation)_ Yς/g 2 cardiac arrest ( = heart arrest )_R\Pbk _d\Pbk 3 The LancetgSRVN[Yyf[Bg_v Ty lancetSIN/fNyYyKb/gRv Ty 4 American Heart Association (AHA)V_OSO ~`N A So far, we have not known exactly yet whether mouth-to-mouth breathing is really useless in CPR. B Only ten percent of the victims treated with traditional CPR survived with good brain ability. C CPR keeps blood and oxygen flowing to the heart and brain. D His studies show that many people do not want to perform mouth-to-mouth breathing on a stranger for fear of getting a disease. E It said people should increase the number of chest presses from fifteen to thirty for every two breaths given. F No mouth-to-mouth rescue breaths were given to them. T{HhN 1 C ,gzz}vYvMRNS/fN~CPR/fNHNN mQ*N y-N Cy_N/fN~CPRv Vdk>e(WNw/fp`S_v0 2 F ,gzz}vYvMRNS ~439MOuNSZP萠RS ,{NkǏ  CPRSb萠RSTS[S|T8T SFy lZPS[S|T8Tv%`Qece /feEQfMRNSv0 3 B ,gzz}vYvMRb$NS0R  S(u萠RSbQeǏegvN'Y_c[k\ g22%X[;m NegvN'YRo}Y c NegُNS[/fN O~v$Nyel~TvbQe!j_\O[k yBck}Y/fُ7hvQ[0 4 E ,gzz}vYvMRNS/f V_OSON2005t^O9eNCPR-N萠RSvc[QR zz}vYvTbSl gc0RYUOO9e yEck}YkXeNُ*NQ[0 N؏la yE-NvIt saidS(uNAmerican Heart Association vQ[zz}vYGW NT0 5 D ُNk/fS_tu;SuGordon Ewyv‰p (WvQ[0Wel gc0RN Vdk yD  His studies show&  [E N]~:NbNcONT{v~"} UOQQ[_NMRTTc0 U.S., European drug officials approve inhaled insulin A form of insulin for people with diabetes to take by mouth is expected to be sold within a few months. The new medicine is called Exubera.1 The United States Food and Drug Administration2 and the European Commission3 both recently approved it for adults. It could make life easier for many diabetics who require daily injections of insulin to control their blood sugar levels. But it will not replace all insulin injections. And it is not for everyone. People who smoke or have stopped smoking for less than six months should not take Exubera. __________(1)__________ Three drug companies -- Pfizer, Sanofi-Aventis and Nektar Therapeutics -- developed the inhaled insulin. __________(2)__________ Experts say about fifteen percent of diabetics who need insulin do not take it. The treatment can involve several injections each day. Insulin is a hormone that the body uses to change food into energy. Failure to control blood sugar levels can lead to serious problems, including blindness and loss of blood flow to the feet. It can also lead to heart disease, stroke and kidney failure.4 Insulin has been sold as a drug since the nineteen twenties. This is the first new way to take it. Exubera uses a powder breathed into the lungs through a mouthpiece. Pfizer will study the long-term effects. It says some patients have reported a mild cough while using the inhaled insulin. __________(3)__________ Many people do not know they have diabetes. There are two forms. Most diabetics have the Type Two form. Their body does not make enough insulin or cannot effectively use the insulin it produces. __________(4)__________ Most Type Two diabetics do not take insulin. Their medicines can be taken by mouth. Diet, exercise and weight control are also important. Type One diabetes often begins in childhood. __________(5)__________ Officials say diabetics with either type could use inhaled insulin, either before or after a meal. But Type One diabetics and some with Type Two would still need a longer-lasting injection at least once a day. ͋Gl inhale vt. 8TeQ vi. 8Tl insulin n. \ } diabetes n. |?\uY?\u diabetic adj. |?\uv n. |?\u` injection n. l\l\m BR therapeutics n. luf[ul lu hormone n. o } w\ stroke n.uu S\O-NΘ mouthpiece n. cS{ lʑ ExuberaNy\ }S8TeQBRvFUT T United States Food and Drug AdministrationVߘTSoT{t@\ European Commission'kvYXTO{y'kYO /f'kvv8^:gg _N/f'kv/UN gCgwIlNv:gg kidney failurepzُ̑failure/f pz va` ~`N A With this type the body is unable to produce insulin. B Pfizer recently bought the rights to sell it worldwide. C The control of their blood sugar levels is most important for patients with diabetes. D It is common in people who are overweight and not active. E Some patients with lung disease should not take it either. F People are advised to have their lungs examined before using Exubera, and at least once a year after that. T{HhN 1. E dkzz}vYvMRNS  bpvNTbp NmQ*NgvN NO(uExuberaُyeo yE  NN` g萾uuvuN_N N(u ُ̑either[E Nw0Rc:y\O(u OMRTS'}[Tc0 2. B dkzz}vYvMRNS0R  N[6RolQSxSNُy8TeQWv\ } HN`HN.UbT yB PfizerlQSgяpN0RhQtv.UCg kX0Ȓُ/fQp`S_ NǏvN0 3. F ,gzz}vYvMRNS0R  gNN(WO(u8TeQW\ }e g{^TU 9hncct6qSُyuNS\Ohg yFck/fُebvQ[ NhgS gNTUMbT|(WNw el\vQkXeQvQ[zz}vY0 4. D ,gkʑ$Ny{|Wv|?\u0 IIW|?\uNvSOel6R Yv\ }bel gHe)R(uSO@bNuv\ } MRb]~0R  SO1\/f)R(u\ }eg\ߘirlSbϑ v @bN9hncct  ր N;mRvN N[f`IIW|?\u0 5. A zz}vYvMRNS  IW|?\u8^8^(W?Qzeg1\_Y sSOl g;Sf[8^ƋvN_N^NMRbN~IIW|?\u-N~b0R,gzz}vYvT{Hh V:NMRb0R  IIW|?\uNvSOel6R Yv\ }bel gHe)R(uSO@bNuv\ } SIIW|?\uNvSOY\؏/fY6R \ }v vkKN N IW|?\uNvSON[ N6R \ } N0 ,{mQR [b_kXzz $N{ Better Control of TB seen if a faster cure is found The World Health Organization1 estimates that about one-third of all people are infected with bacteria that cause tuberculosis . Most times, the infection remains inactive. But each year about eight million people develop active cases of TB, usually in their ____1____. Two million people die ____2____ it. The disease has ____3____ with the spread of AIDS and drug-resistant forms of tuberculosis. Current treatments take at least six months. Patients have to ____4____ a combination of several antibiotic drugs daily. But many people stop ____5____ they feel better. Doing that can ____6____ to an infection that resists treatment. Public health experts agree that a faster-acting cure for tuberculosis would be more effective. Now a study estimates just how ____7____ it might be. A professor of international health at Harvard University2 led the study. Joshua Salomon says a shorter treatment program would likely mean not just more patients ____8____. It would also mean ____9____ infectious patients who can pass on their infection to others. The researchers developed a mathematical model to examine the effects of a two-month treatment plan. They ____10____ the model with current TB conditions in Southeast Asia. The scientists found that a two-month treatment could prevent about twenty percent of new cases. And it might ____11____ about twenty-five percent of TB deaths. The model shows that these ____12____ would take place between two thousand twelve and two thousand thirty. That is, if a faster cure is developed and in wide use by two thousand twelve. The World Health Organization ____13____ the DOTS3 program in nineteen ninety. DOTS is Directly Observed Treatment, Short-course. Health workers watch tuberculosis patients take their daily pills to make ____14____ they continue treatment. Earlier this year, an international partnership of organizations announced a plan to expand the DOTS program. The ten-year plan also aims to finance research ____15____ new TB drugs. The four most common drugs used now are more than forty years old. The Global Alliance for TB Drug Development4 says its long-term goal is a treatment that could work in as few as ten doses. ͋Gl cure n. ul luoo bacterium ( pl. bacteria ) n. ~̃ tuberculosis n. ~8hu inactive adj. N;mÍv ^;mR'`v antibiotic adj. buv n. bu } infectious adj. Og'`v infection n. Og ag Ogu mathematical adj. pef[ N v partnership n. T\O TOT\OO4O TON alliance n. Tv Tv lʑ 1. World Health Organization (WHO)NLukSu~~ 2. Harvard University ( = Harvard )V T[O'Yf[ 3. DOTS ( Directly Observed Treatment, Short-course )wgvc‰[lu 4. Global Alliance for TB Drug DevelopmenthQt~8huoir_STv ~`N 1. A) kidneys B) lungs C) bones D) livers 2. A) with B) without C) of D) out of 3. A) increased B) decreased C) changed D) disappeared 4. A) make B) take C) try D) test 5. A) as if B) as though C) as far as D) as soon as 6. A) refer B) apply C) lead D) amount 7. A) effective B) ineffective C) expensive D) inexpensive 8. A) cured B) to cure C) being cured D) having been cured 9. A) many B) more C) few D) fewer 10. A) provided B) introduced C) tested D) tempted 11. A) bring about B) contributed to C) promote D) prevent 12. A) increases B) reductions C) creations D) collections 13. A) developed B) invented C) delayed D) refused 14. A) easy B) uneasy C) sure D) unsure 15. A) with B) to C) onto D) into T{HhN B ~8huYSN ُ/fN,v8^Ƌ0 C0die ofa`/f {kNgyuu vQ[ N*NN͋ NNdie-dM0 A0,gSTJS0R 1uN~nuv OdTboW~8huvQs HN9hncct ~8hu6q^勞XR NS Q\ b m1Y 0N SS N^/f~8hu,gSuSS ^/fSusSuSS0 B0N,gSvMRTSSNcKm0R,gS`v/f uNk)Y_{ g(uQybu }oir goS btake vQ[Q*NR͋ NT0 D0T{elaSvButُ*N͋ >f6qN NSa`Sulb V*N y-Nas if0 as though/f N[O [Y va` as far asR/f N& 1\&  va` kX(Wُ̑GW NT S gas soon as  N& 1\&  Mbp`S_0 C0,gzz}vYTb gN͋to }6qُQ*N yGWSNtoޏ(u FOa`T Nv Trefer toS Sapply toc=m (uNlead to[amount toT ;`qQ& S g bleadMbO,gSa`[te0Qnx0 A0S(u_la NbS݋1\SN_[f0W~b0RT{Hh >f6q,gS` s(W gNyevxvz`ċ0OُyHeluBRvzzHeR gY'Y 0 A0,gSgv/fl09hnc@b~vR͋ bNSNs0R,gS`v/f Joshua Salomon u zwvluRSasT@w NNN/ffYuNl}Y 0ُ̑NlRg ^/f:N*N[ Oppatients cure/fN*NSirR͋ uN^/fluByto cure Nh:yRCTD}6q gh:yRva` FO/fC/f ck(Wlu D/f ]~lu $N+Tve`(Wُ̑GW NT S gAMb/fp`S_v0 D0MRS0RfYuNSNla 9hncct TS^/f \ag O~+RNv OguN1\Of\ V:NMRT$NS[E NwQ gVgsQ|0ُ̑_{(uk~fewer V:Nfew/fh:y NYv QNNl gv= not many  fewerRS/fNNMRk f\ v^l gfnxY\0 C0S gkXCytestedh Mb&{T N Nea` vQ[ Ny NN͋IN NT ͋v(ul_N N[0 D0zz}vYv NNS[E Nw0Rc:y\O(u $N*NgvlueHhSN2bk'Y~20%veuO TS6q^/f _NS2bk'Y~20%v~8hu{kN 0vQ[ N*N y͋INGWvS0 B0 Nb$NS0R SN2bk'Y~20%veuOTS2bk'Y~20%v{kN ُ6q/f MNO ~ NS/f XR f N/f R\OT 0 6eυT 0 A0zz}vYv NNS[E N_Nw0Rc:y\O(u SNcKm ,gS^/f 6RDOTSR V*N y-NS gAy g 6R va` R_N NS/f Sf N N NeRg f NS/f cߏ b b~ 0 C0DOTSRvQ-N1\S+T vc‰[ va` ,gS-N_N0R ;SRNXT w@w~8huNk)Y go vv6q/f nxONN~~lu Cymake sureck/f nxO va`0 D0researchTb8^(uonb into vP\_N(u forb after OYa research for/after facts[N[vg FO NNvQ[ N*N yޏ(u0 Once-daily pill could simplify HIV1 treatment Myers Squibb and Gilead Sciences have combined many H.I.V. drugs into a single pill Sometimes the best medicine is more than one kind of medicine. Malaria, tuberculosis and H.I.V./AIDS,2 for example, are all treated with ____1____ of drugs. But that can mean a lot of pills to take. It would be ____2____ if drug companies combined all the medicines into a single pill, taken just once a day. Now, two companies say they have done that for people just ____3____ treatment for H.I.V., the virus that causes AIDS. The companies are Bristol-Myers Squibb and Gilead Sciences. They have ____4____ a single pill that combines three drugs currently on the market.3 Bristol-Myers Squibb sells one of them ____5____ the name of Sustiva.4 Gilead combined the ____6____, Emtriva and Viread, into a single pill in two thousand four. Combining drugs involves more than ____7____ issues. It also involves issues of competition ____8____ the drugs are made by different companies. The new once-daily pill is the result of ____9____ is described as the first joint venture agreement of its kind in the treatment of H.I.V. In January the New England Journal of Medicine5 published a study of the new pill. Researchers compared its ____10____ to6 that of the widely used combination of Sustiva and Combivir. Combivir ____11____ two drugs, AZT7 and 3TC.8 The researchers say that after one year of treatment, the new pill suppressed H.I.V. levels in more patients and with ____12____ side effects.9 Gilead paid for the study. Professor Joel Gallant at the Johns Hopkins School of Medicine in Baltimore, Maryland, led the research. He is a paid adviser to Gilead and Bristol-Meyers Squibb as well as the maker of Combivir, GlaxoSmithKline. .8JLVZ^t~0:V`bdfjlnpϱϱϱϱϱϱ흉xdUhr\h8B*aJo(ph&h/h85B*CJKH\o(ph h85B*CJKH\o(ph&h[h85B*CJKH\o(ph&h%eh%e5B*CJKH\o(phh!OB*KH\aJo(phh"K B*KH\aJo(phh%eB*KH\aJo(phhG;B*KH\aJo(ph#h%eh%eB*KH\aJo(ph<dfn4L WD^ `gdkQ iWD2`igd6u\WD8^`\gdkQgdkQ\WD8^`\gdlONUDaVDWDd]^N`gdkQ UDa]gdkQNvUDaVDWD,]^N`vgd"K p,24<P±񢑀o^^^Ohr\h8B*aJo(ph hr\h"vB*KHaJo(ph hr\h%eB*KHaJo(ph hr\hr\B*KHaJo(ph hr\hWCB*KHaJo(phhr\hWCB*KHaJph hr\h!OB*KHaJo(phhr\h%eB*KHaJphhr\h!OB*aJo(ph hr\h%eB*KH\aJphhr\h%eB*aJo(phKP 06PԯԯԥʕԄzzmYOEOEh"vB*o(phhWCB*o(ph&h Ih85B*CJKH\o(phhn0h*\lB*o(phhB*o(ph!hn0hmB*CJKHaJphhmB*CJKHaJo(phhG;B*o(ph!hn0hB*CJKHaJphh%eB*o(phhmB*o(phh8B*o(phh8B*KH\aJo(ph#hn0h85B*CJKHo(ph~2'ad,1$WD`gd/BV WD^`gdkQHWD8^`HgdkQ\WD8^`\gdkQNUDaVDWDd]^N`gdkQgdkQ iWD2`igdkQ \VD2WD8^ `\gdkQ PR\b|~(02>  >&>ξδΣschG;B*CJKHaJo(phh*\lB*CJKHaJo(phhWCB*CJKHaJo(phh\WB*CJKHaJo(ph!hn0hWCB*CJKHaJphh\WB*o(phh3cuB*CJKHaJo(phh3cuB*o(phhhuB*o(phh*\lB*o(phh"vB*o(phhWCB*o(ph#>Rv|~'H_`aƼޜ{qjj_N!hqph*\lB*CJKHaJphhqpCJKHaJo( h|H*o(h|h|H*o( h|o( h|h*\l)hX;h*\l0JB* CJOJQJaJphhWCB*CJKHaJo(phhG;B*CJKHaJo(phhG;B*o(phhG;B*CJKHaJphh\WB*o(phh\WB*CJKHaJo(ph!hn0hG;B*CJKHaJphaghg6 M N @ B H J L ` d n r t ꠐ~teSDSDSh3y0J5B*aJo(ph#h16h160J5B*aJo(phh160J5B*aJo(phh|B*o(ph#hn0h|5B*CJKHo(phh|0JB*CJaJo(phh|h*\lB*aJphhpB*CJaJo(phh|B*H*aJo(phhqpB*CJaJo(ph&hqpB*CJOJQJ^JaJo(ph)h|h*\lB*CJOJQJ^JaJphajN @ B J v    $ X |      r   & FgdkQNUDaVDWDd]^N`gdkQ WD`gdlOgdkQ WD`gd/BV$d,WD[$\$`a$gd/BVt v        " > D V X n z               V l p ұ|ha\WRa\W h|o( h16o( h3yo( h|h16&h/h|5B*CJKH\o(ph h|5B*CJKH\o(ph&h[h|5B*CJKH\o(phh|0JB*CJaJo(ph#h16h|0J5B*aJo(phhkX0J5B*aJo(phh3y0J5B*aJo(phh160J5B*aJo(phh|0J5B*aJo(ph p r       " 4 6 8 > @ B F    ųpaTEa8ah|hqpB*aJphh|0J5B*aJo(phh|hpB*aJphhqp0J5B*aJo(ph#hqph|0J5B*aJo(phh|B*KH\aJo(ph#hn0h|5B*CJKHo(phh|0JB*CJaJo(ph#h16h160J5B*aJo(phhsB*aJo(phh|h16B*aJph h16o( hso( h|h16h16h16B*\aJo(ph 6 8 @  mVWVB $d1$a$gdkQ\WD8^`\gdkQNUDaVDWDd]^N`gdkQgdkQ & FgdkQlpUVVdvx|:<>JԻvdvvUUCUU#hph|0J5B*aJo(phhs0J5B*aJo(ph#hphs0J5B*aJo(phhs0J5B*aJo(ph#hphp0J5B*aJo(ph&h Ih|5B*CJKH\o(phh|0JB*CJaJo(ph#hqphqp0J5B*aJo(ph h|hqph|hpB*aJphhqp0J5B*aJo(phhp0J5B*aJo(phJ~Pd@PfhҴҴᴥåår_Oh*\l5B*CJKHaJph$hX;h*\l5B*CJKHaJphhn0h*\lB*o(phh*\lB*o(phhXB*o(ph#hphp0J5B*aJo(phh[0J5B*aJo(phh&F0J5B*aJo(phh160J5B*aJo(phhG0J5B*aJo(phhp0J5B*aJo(phhs0J5B*aJo(ph$^`PW`iFOdm"!ӵӧӁsӁӁӁӁӁӁeeeehgPB*KHaJo(phh1+B*KHaJo(phheB*KHaJo(phhCjB*KHaJphh%yB*KHaJphh%yB*KHaJo(ph h1+h*\lB*KH\aJphh1+B*H*aJo(phh1+h*\lB*KHaJph!hX;h*\lB* CJKHaJphhX;hX;B*o(ph'$"@BJlLx @ B J   WD`gdVNvUDaVDWD1]^N`vgdkQgdkQd,1$WD`gdV$`d,1$WD``a$gdkQFQ@BHJZjl2IJn`OOOOO hcjh.}B*KHaJo(phh&B*KHaJo(ph hcjh*\lB*KHaJo(ph hcjhSq+B*KHaJo(ph hcjhB*KHaJo(ph h1+5B*CJKH\o(ph#hn0h1+5B*CJKHo(ph!hn0h*\lB*CJKHaJphh1+B*H*aJo(phhgPB*KHaJo(phh1+h*\lB*KHaJph2:BHlt 2 < @ B J R           ! !!n!!!!!!޿rbrrrh*\lB*CJKHaJo(phhcjB*KHaJo(phhCjB*KHaJo(phh1+hCjB*KHaJphh1+B*CJKHaJo(ph#hn0h1+5B*CJKHo(ph hcjhB*KHaJo(phhVB*KHaJo(ph hcjh.}B*KHaJo(ph hcjhcjB*KHaJo(ph& !!!!!L"""9###2$$$'%z%%B&&v'x'''((B) & FgdkQ $d1$a$gdkQgdkQ!!!" """"""$"+"."3"9"@"C"I"L"M"S"W"^"d"g"n"s"y"|"~""""""""""""""""""ͿͿͱͱͿͿͿ͔ͿͿͿͿͱ͆Ϳ͔w͆ͿͿͿh1+heB*KHaJphheB*KHaJo(phhimB*KHaJo(phh1+h%yB*KHaJphh%yB*KHaJo(phh.}B*KHaJo(ph h1+himB*KHaJo(phh1+5B*CJKHo(ph#hn0h1+5B*CJKHo(ph.""""""""### #### #&#/#2#6#9#:#@#E#L#R#U#^#c#g#j#s#y#~##########################$$ $ $$$$!$hixB*KHaJo(phheB*KHaJo(phh1+heB*KHaJphhimB*KHaJo(ph h1+himB*KHaJo(phh.}B*KHaJo(phB!$$$/$2$3$9$>$E$J$M$T$Y$`$c$n$r$u$x$$$$$$$$$$$$$$$$$$$$$$$$$$$%%%%%%%$%(%)%/%>%@%C%Q%U%W%hgPB*KHaJo(phh1+hgPB*KHaJphheB*KHaJo(phh1+heB*KHaJphhimB*KHaJo(phhixB*KHaJo(ph h1+himB*KHaJo(ph'F'R'`'b'h'p'v'x''''''''''''ﱟscSCShSXB*CJKHaJo(phhCYB*CJKHaJo(phh1+B*CJKHaJo(phhCYB*KHaJo(phhB*KHaJo(phhimB*CJKHaJo(ph#hn0h1+5B*CJKHo(ph$himh1+B*CJKHaJo(phh1+hgPB*KHaJphhimB*KHaJo(phhB*KHaJo(ph h1+himB*KHaJo(ph''((((((()"):)D)F)))))))))))***,*0*2*4*6*8*B*H*J*\*`***********´ФДvvvvvvvvhVB*CJKHaJo(phhxB*CJKHaJphhxB*CJKHaJo(phh"BB*CJKHaJo(phh"BB*KHaJo(phhCYB*KHaJo(phhSXB*CJKHaJo(phhimB*CJKHaJo(phhCYB*CJKHaJo(ph.B)F*<++L-\..j//0r1&2(2*224z679xy{ WD`gd{#x$d,WD[$\$`a$gd{#x WD`gd{#x `WD``gdkQgdkQ & FgdkQ*****++++4+>+@++++++,,r,,,,,,,,,,,,,,8-:-F-J-L-N-ಢಢrrbrrrrbrbrrh(-B*CJKHaJo(phh%yB*CJKHaJo(phhgB*CJKHaJo(phh5NB*CJKHaJo(phhN9"B*CJKHaJo(phhSXB*CJKHaJo(phh B*CJKHaJo(phhVB*CJKHaJphhimB*CJKHaJo(phhVB*CJKHaJo(ph&N-P------&.0.Z.^.`.f.h.j.v.....b/l/n/r/z/|//////0>0F0^0`0l00𠐀ppp`hK~B*CJKHaJo(phhf B*CJKHaJo(phhrUB*CJKHaJo(phho>qB*CJKHaJo(phhM_B*CJKHaJo(phh^B*CJKHaJo(phh%yB*CJKHaJo(phhrB*CJKHaJo(phhxSB*CJKHaJo(phhSXB*CJKHaJo(ph%00000@1B1D1V1j1r1t1v111111111111$2&2(2*2n2p222"3~n~_X hn0h*\lhX;h*\lB* CJaJphhX;h ZB* H*aJo(ph)hX;h*\l0JB* CJOJQJaJphhX;B*CJKHaJphh1+B*CJKHaJph!hh1+B*CJKHaJphhB*CJKHaJo(phhSXB*CJKHaJo(phhoJB*CJKHaJo(phh%yB*CJKHaJo(ph "3$3.333 4)444j4o4s44455555556666616:6666647=7778888Y8c8´Ω”{g{{{&h ZB*CJOJQJ^JaJo(phh ZB*H*aJo(phh_B*aJo(ph)hn0h*\lB*CJOJQJ^JaJphhus&h*\lB*phh ZB*KHaJo(phh ZB*aJo(phhn0h*\lB*CJaJphh ZKHaJo(h ZH*aJo( hn0h*\lhus& hus&o((c8r8s8|8}888 9 99xxx x xx$xyyyyynzz{{{{{{{꬞ݐ~m^hkh3DDB*aJo(ph h3e5B*CJKH\o(ph#hn0h3e5B*CJKHo(phhus&B*CJaJo(phh_B*KHaJo(phhn0h*\lB*CJaJph&hus&B*CJOJQJ^JaJo(phUh_B*aJo(phh ZB*H*aJo(ph)hn0h*\lB*CJOJQJ^JaJphGlaxo Smith Kline reacted ____13____ the findings by saying that a single study is of limited value. It says the effectiveness of Combivir has been shown in each of more than fifty studies. The price of the new once-daily pill has not been announced. But Gilead and Bristol-Myers Squibb say they will provide it at reduced cost to developing countries. They plan in the next few months to ask the United States Food and Drug Administration10 to ____14____ the new pill. There are limits to who could take it because of the different drugs it contains. For example, ____15____ women are told not to take Sustiva because of the risk of birth disorders.11 Experts say more than forty million people around the world are living with H.I.V. ͋Gl pill n. o8N simplify vt. {S malaria n. uu tuberculosis n. ~8hu virus n. uk joint adj. TTv qQ Tv venture n. QiNN suppress vt. b6R approve vt. ybQ pregnant adj. Y Zv gU[v competition n. zN lʑ 1. HIV ( human immunodeficiency virus )NMQu:wuk 2. AIDS ( acquired immunodeficiency syndrome )_'`MQu:w~T_ ~nu 3. be / come on the marketQ.U 4. SustivaNSTbQsvEmtriva0VireadTCombivir/flu~nuoirvFUT T0 5. New England Journal of Medicinee}F}}&~f~~JWDj^J`gdkQNUDaVDWDd]^N`gdkQ WD`gd'NvUDaVDWD1]^N`vgdkQgdkQ{{{{|||@|J|^|b|z||||||||}}}0}4}6}:}<}>}F}N}}}}~өyk]yhYB*CJaJo(phh3eB*CJaJo(phh7OB*CJKHaJo(phh_B*CJaJo(ph#hn0h3e5B*CJKHo(phhkh3eB*aJo(phhkhkB*aJo(phh'B*aJo(phhkh3DDB*aJo(phhkh*\lB*aJo(phhkhtB*aJo(ph!~$~&~.~^~d~n~|~~~~~~~~~~ $*ĶĶĶĶĶҗscSCSh`B*CJKHaJo(phhkB*CJKHaJo(phh7OB*CJKHaJo(ph hTh7OB*KHaJo(ph$hn0h7OB*CJKHaJo(ph!hn0h7OB*CJKHaJphhkB*KHaJo(phhkB*CJaJo(phh`B*CJaJo(phhYB*CJaJo(ph#h7OhYB*KH\aJo(phh7OB*KHaJo(ph*,<Phj̀΀ހ*@DLR񭜍~o^o~o^N@h+5B*CJaJo(phh+5B*CJKHaJo(ph h+5h+5B*KHaJo(phh+5h+5B*aJo(phh+5h`B*aJo(phh+5hYB*aJo(ph h+5h`B*KHaJo(ph h+5hkB*KHaJo(ph$hkhkB*CJKHaJo(phh`B*CJKHaJo(phhkB*CJKHaJo(phhkB*CJKHaJphDdLP5ׅ$xʆ^gdkQ\WD8^`\gdkQHWD8^`HgdkQ؁@LbnԂ؂ڂ$*FLNZhv|̃҃򹧘yky\yyk\kkyyhn0hWnDB*CJaJphh_B*KHaJo(phhus&B*KHaJo(ph h1+h_B*KHaJo(phh3e5B*CJKHo(ph#hn0h3e5B*CJKHo(phh3eB*CJaJo(phhn0h`B*CJaJphh+5B*CJaJo(phh`B*CJaJo(phhYB*CJaJo(ph$҃  &),28=@JMPQW_fhjksy{~ń˄΄ӄل߄ӶᨶӶӶӶ h_h_B*KHaJo(phh&`rB*KHaJo(phh@B*KHaJo(phhn0hWnDB*CJaJphh_B*KHaJo(ph h1+h_B*KHaJo(phhus&B*KHaJo(ph;"),2456<BILMOPY_abemsvwzÅƅȅ˅ԅօׅ؅ޅӥhUWB*KHaJo(ph h_h_B*KHaJo(phhn0hWnDB*CJaJphh_B*KHaJo(ph h1+h_B*KHaJo(phh@B*KHaJo(phA !#$%&,07<>?DJPS]cehuwxyzdžɆʆˆ̆҆Ն܆ӥh&`rB*KHaJo(phhxyB*KHaJo(ph h_h_B*KHaJo(phhn0hWnDB*CJaJphhUWB*KHaJo(phh_B*KHaJo(ph h1+h_B*KHaJo(ph;  %&+-.28?@CEKQRSTW[]^_`fqvxyŇLJȇ·ԇߵߤõѵߤõߵߤõ h_h_B*KHaJo(phhxyB*KHaJo(phh&`rB*KHaJo(phh_B*KHaJo(ph h1+h_B*KHaJo(phhn0hWnDB*CJaJph@ԇۇއlnȈ̈Έᨖzl^P^BzBzh B*CJaJo(phhVLB*CJaJo(phhliB*CJaJo(phhB*CJaJo(phht$SB*CJaJo(phh0<B*CJaJo(ph#hn0h3e5B*CJKHo(phh3eB*CJaJo(phhn0hWnDB*CJaJphhxyB*KHaJo(phh&`rB*KHaJo(ph h1+h_B*KHaJo(phh_B*KHaJo(phʈtd‹>~ȩ^ʪ@ gdQRgdQR$a$gdQR & FgdQR & FgdkQ $d1$a$gdkQΈBJrvxƉ *NTV^`~ĊȊ֊ R^bfhċƋ΋<@BJdȺ亮ֺȒȒȂhu[\B*CJaJo(phUh7B*CJaJo(phhI/B*CJaJo(phhGB*CJaJphhGB*CJaJo(phht$SB*CJaJo(phh0<B*CJaJo(phhVLB*CJaJo(phhHB*CJaJo(ph/S gS_ N ToS6R TN{|oTeMbOQs @bNS gifMbT0 C0,gS-N the result ofTb^/fN*N[NS zz}vY^/f[NSv;N HQbNSNcdthatTwhich V:N[N/f(uegޏc[NSv vQ[$N*N what = the thing(s) that whatever = any thing that $Nvk ^whatp`S_ V:Nُ̑cv/fwQSOُN!k N/flcNUON!k0 D0xvzNXT[ N ToirۏL[k 6q/f[k[NvuHe vQ[ N*N yv[kGWkeaIN0 B0V*N y-NS gATBSNQ exclude/f dY cd N contain S+T +T g ckvS Vdk sSO/f NwSAZTT3TCSNlu~nuvN_NO bBy V:N\O~ NO(Wl gfAZTT3TC/fNHN7hvoirvQ N1\ NS+T[N Ygُ7h1\Oxd N@w4Y0 B0e6qُyeoSNb6RfYuNvHIV4ls^ oR\O(u6q^ f\ ُ/fO(ueoMRTv[k Ee_{(uk~0 C0react to [...\OQS^ /fV[(ul vQ[ yGW N[0 D0N,gSW[b N w NNSb{(WQ*NgQBlFDAr^NHNN`bT N/fNeo gsQ FDAS/f[yboTv:gsQ 6q/fapprove ybQ N0 D0,gSTb]~c0R ueS gqSi 1\S gU[Y (pregnant women) Mb guvN0  INCLUDEPICTURE "http://www.chinaacc.com/upload/news/2008/1/16/lilu817420081161422129145.gif" \* MERGEFORMATINET  00-NNSOQ!hLy틅[ z(W^'Yf[XT-NS_N^8^}YvST 'Y[nfMS fMR['}4}TRT vQՋ|Ӛ aɉSvoY Y`NNJSR P0:NNb2008t^LyՋvf[XT gfEQveY YYeQ 2008t^LyՋQ N[ _YhQbbu  HYPERLINK "http://www.chinaacc.com/login/pay_reg_new.asp" \t "_blank" 2kbN 00YeQ2008t^LyՋ[ScQ l͋Gl|s [ccNW,glN͋Glvu '}[~TSt^Ջĉ_Tw [Ly_vlT͋GlwƋۏLƖ-N .^Rf[u(W Y`NǏ z-NX:_l͋Glf[`Nv['`T[(u'`0hQ zƉc N[24\eT{u f[XTN9KNewS NPe0!kpe͑ Ypdf[`N v0RS_gՋ~_gTNhTsQ  HYPERLINK "http://www.chinaacc.com/login/pay_reg_new.asp" \t "_blank" 2kbN 00 INCLUDEPICTURE "http://www.chinaacc.com/upload/news/2008/1/16/lilu8997200811614293056020.gif" \* MERGEFORMATINET 0 HYPERLINK "http://www.chinaacc.com/wangxiao/gonggao/english/2008englishfa.htm" -NNSOQ!h 2008t^LyQ N[ bueHh 00 INCLUDEPICTURE "http://www.chinaacc.com/upload/news/2008/1/16/lilu8997200811614293056020.gif" \* MERGEFORMATINET 0 HYPERLINK "http://www.chinaacc.com/demo/english.htm" 2008LyQ~ zMQ9Ջ,T      ONvQ N[V PAGE 34 b TT5u݋010-82318888 MQ9p~: 4008104588 Ow010-82330766 PAGE 34 dJZb4Bntv|¨  *0v|Ʃʩ̩کܩ :HX\`b京ȬȞȞhrB*CJaJo(phh_B*CJaJo(phhB*CJaJo(phht$SB*CJaJo(phh0<B*CJaJo(phhI/B*CJaJo(phhB*CJaJo(ph>Ȫʪ̪FHPR02:<DF*,.024԰ְ  ʶ®ttct!hQR0J5B* CJ\aJph3jhQR0JCJUaJhQR0JCJaJji hQRCJUaJhQR0JB*phjhQRCJUaJhQRCJaJjhQRCJUaJhQRCJaJjhQRCJUaJhQRB*CJaJo(phhrB*CJaJo(phhI/B*CJaJo(ph" ln ݺݰ{jb^b^b^b^QJC hkhQR hQR5o(jhT:hQR5Uh+n~jh+n~U hQRhQRB*CJaJo(phhQR5B*\ph!hQR0J5B* CJ\aJph3hQR0JB* ph3jhQR0JB* Uph3hQR0JB*ph&jhQR5B* CJU\aJph3hQR5B* CJ\aJph3&jhQR5B* CJU\aJph3hQR0JB* CJaJph3"$<>@Bijܳ޳gdQR$a$gd& 5&#$gd&gdQRgd& &`#$gdxegdQR "$&248:<@B^bhtijƳҳԳسڳܳʾʾʾʾ hQRhQRB*CJaJo(phh4>h+n~hQR0JmHnHuhQR5OJQJ\o(hQR5OJQJ\ hUc5hUc0JmHnHu hUc0JjhUc0JUhUc hQRhUc0182P. A!"#$%S P$$If!vh5#v:Vl: t65a$$If!vh5#v:Vl t065aP$$If!vh5#v:Vl t65a$$If!vh5#v:Vl t065a DdLXx  S TA4lilu817420081161422129145b UZ= mkCs7,g} n UZ= mkCs7,g}PNG  IHDR(?X'tEXtCommentCreated by IBM HomePage BuilderCMPLTE[@@V[etRNS@fbKGDH cmPPJCmp0712HsIDATx^Zz0 LKgN?Sn_k`I}dqzݬ_\7b]_(苇ߩ~% fzީ~ = Y}=u{U?m [x?yv-z{mܜK(in+zYciL~`d`g]GNN |oXcDꏱp-cUdu|t"^l=l3zZHRp~W Av{Z E8;جu?5=[x#*Ks?H=mmi^xV1һ@˯g;UB#- -z'<zDGU?K ;hπ˧c{r<$y,'&wQ%hl6$@t= ly_.\{[z9iGC@|'&lKM2]50T+$W/"Stpֿ3)PU? )RrAdjĕ悉,9,#H7 DI $݉0M;&Лw5PyMR]^ &}bs6z@V&Z o{U/bDvuù4C +TUA/F6bДx:LWyКOP!TJ r -39U^ƭi|q^1; y#5EpkgfŗYg2 /^>ؖsܪ1m\͈0,++Y/OidW Wo6{\UopKWDB-ͶFf.w WX]l\ IBMW]qr(A[&P q[eZTW;%2-4mHlltx*s7Ђ;OE/bq؆ƥk7mRBQ <Ԅ=ݪT rS#M}J5K1p4F mN;k)'HOmIENDB`Dd**z  S VA6lilu8997200811614293056020b˒7|jL [n˒7|jL PNG  IHDR +tgIFxNETSCAPE2.0$NP PLTEitRNS AbKGDf |dgIFg P% cmPPJCmp0712OmIDATcXj/h` A@z) GNHmsOGMSOFFICE9.0GIF89a ! NETSCAPE2.0! ,  \H7}p! ,  ܁TB޿UQ! , !^IENDB`DDdZ  C 6AQ!hlogo(>e(Wech̑v)RVC^}ۋy5 x2C F*C^}ۋy5 xJFIFHH,Photoshop 3.08BIMHHAdobed4     u!"1A2# QBa$3Rqb%C&4r 5'S6DTsEF7Gc(UVWdte)8fu*9:HIJXYZghijvwxyzm!1"AQ2aqB#Rb3 $Cr4%ScD&5T6Ed' sFtUeuV7)(GWf8vgwHXhx9IYiy*:JZjz ?ߺ^׽tU{gCnvKu}IM.[kI+sI|iz<L^713ɴPBm,W ZV4qp0ƲKo_Tp 5 -!U5-MHO Dk5E;I2-EDp3̢jZ)$G{{^׺uw?0ꏁ;av|,\\]ؽnN3nÝbjւZף>:O|p_ۖv?Vm>ܻCnٿ0!nh hIZpעZɶԷ!A \O+Cg|0CrL~F`r}e>dcC+EOiJS'7[mq1-rȪ#"*qׯ8'Ա #ȒO=3;k*}򑶟d񶛤>Er\xm`2KT ԕssUڽ;{`ۮbY#]Hªt£ɔDso3A4eF hG)F?ɫeGhk~wuem=7hؿ?z>'vvݙ3c./5%G@);#hlsICO —u~lnh{myn'BSClI;]қa-۔}A3x\6ed*6;f3 ;2#"v}x8 2R0azW쥌'  {xmؽ_+Cqme 3[3RbX,Ҥu%eD܍[=ovGk,3$WV*Hc\Prm˂ZTTҦcrgjm;#uaE\SßUy"S&&uHe&C J{s' # hC  Ȟ<3*l`ϑLJBg׺ugS[IղK7/Usg}Ǒ X۝7LV@UhR7V%mgi+ ˹}yN 2\oEfifnأAj#[tfSoj DžNS*C1ڸ,k' 3*FZy^zeiًdr)W([QTg>Jz߻n<4)wCĒѬ\+D(ȪQ0^WP=[ڹLv"-=cw}S`鄹 r;dvܘS5n滸u\J0*@QSA@ɧ]ZHBhA&@ >@-eF!x(Y骩j`gWGF*AVV* X0 ">[׺գ{'O_l^ހ=wl)w%Ij>g I]ڤTB+ IP}nי/lm洰IbhP]DC+NN>]IU"Gd*`4#|O+f?l/6'?߽ܺ;_ܽ_K.ڙ m_5CJLL,_7w{ݦ 81tBL|'5;iJ6g$ʷrMZTter2it`[F{mN5*(;~me~AsN =Z#cCUAauTC[h**v|w~W۶dzxmB3E6Ax4 kқgۮ| fL@} _>a9]{rms۶sٷ̣jm;ՐaxM͇BkᬧOV+ S͊܃βrw,o..'PDrhYY *Y .`53HNy ZSן>w7}/~ f _^z^A*o53&B:Xhl>jYb{/r/ݍyk')pn@:bʼnQZ04Ź>*m*6^ {psqd|a +τΟ1}{_MY^S*r OwOOi9og|crrm3\eH5VvS{{'LGVZRG|nO=q'魯O٭G?g6<ۙq8ՏZ%jHjY#8olۖ]8vxc2GDu؏U:h'-.02hr+JzSǭJ{Cwo~?ߖ8]asG`=ѽW.毤 *NܡT& δɇ)yהo9K-kڝeHnknKFч;%b w7xpRG%?Wҵ8Ձ4?c{oʟ:3_#O_?{62nՓv`fԧo̬re1FJevܩfoV\,62vh毡sj8GFP,$gR$RBPRiQAvr:`yzjvZ*5Gd@n ~ŗRf+t_II9#xռXOɰB%B-Jg YQu0 'L"Ÿ254 5΄uV}3?0yzeJc६htR%Bed$ܽ%vך8~:Ɗw'Efat̠:UbS '.c s0RIA פ/̪=;cǔ{#Wɮﱻ'zۓ[prw>bKT_%]>zw~nDw m 9!KZiхFdTٷn[tjygv@x׉T:(=6_z-im߿{ߢ{[tGeSǖ77^*(sd.DnbĿ"ms[G?F)Ӫ'*k-+82xj6KK+]|`XЭ hEMkJ1]=C{ut54T4TUVU5-%-4m5EMMD̐O(]UPI ~k_gqfsFm540QL\ed!kb6>`6Y 8V''F{aXs۬H4 P PjhO{OճU&wgu~,]̓v\7qUm~K%6Boɐ!w9Kq&}~TFİ]?ȼew.i7;#5n *c/icxh6Z=dOC#FaWWJ67[8j\HөplM60S$"+1T0M:4N*izOrOf5Jm9V<)z#;3{k+:g ϙo23Μ>-fʆ(@RiF){ǯ{^꺿/qQ!Qw1;bwV?k 6b9-fOUJm1SI!AQ!~Iu// \ʅRekPq=vZ$i4JӭIrCǺLN>R|n=uCfú S)S>W_CB)og+i6ͻƄA@D5Pc>^mۆitZzq6O&hcil>[_;Z,6;ņ3I' Zy#Jg6e/ʕ/>^}xl^B,QqCF4$ 1Ў>Tb&wyQZCm^#z_fcwm/=F1L~qugRWu>d/Q.۸/>4FMJuBHP<<4JdXQCy˭G?SGCvή=ys:wc7ˏݕ9 |XRGkUcE\י}ti[X%u8;I$RViXmEV5T%UG/+##}3Ul6vSt77 -S S<"ft2<9B^Y]mm&$ tV`h~ :_FEbBEGϴ??@윦O;lC}~]}ڤml^஭aa⦡"Q< A=dQMC BI?PиA$_Mriv\25#WΗ~!|1a_1]߹-~K|O(3cv_Ym-ϸ~'H_-4N(iᮭuo9xy6׀=7sW:$lh` (5ƛvP]-`wNŧOT7Mfs|`bhw]Vٽ?\oj,Zz˔4u䧨+nSϚaV6TI TYk?P)1j_ݰ_G ]\Id*&Cy0fu:ѱGZ|}֝펼ڽmp#w>|jQmㄢa=f{Եu,AS֊;~`K[n$i!Dh',u"IJ5I$R:8ⶎ8J&`0k֥Ƴ@w+OmocNN+0B+k`3q52Q}5NRrRIqo/+~oQIMZTEu2cY@We†#j*|Bh p ۵>Crv܉Ӹ "Zu>ܛ4S; y@$14[76162l xFbHc,kIN‚}H1g=?C);4?/[~/_o[Ba~۽Ց>zA>/-I3KѽT%tS.p|gޛe;I F ZOv{yrY--۠"-lf!q2I,\dհ@x@1hzG;+׺_ESv۟6VM&-ɦ]~+>d:hk~NnLmVӍ 6֣$UTtrF@TpX zyK[ ?v[$3^:ȡ`||E9$R[ޞ&'dSWKC#I-|PS,mfυ7bG%x#R\)WMRg2=)m>hf$QIN2OZ\#wb-Y }ēu7jiZRZ W:uSנs~5tGz޽;knt݉22ԻTdamY]2q[mwg\&)iIc!T1N'&tt ':}ftoJuߝם=ջrd;|ξ[_xv6J:s`9]nFe!=DYpu;gyo;w3[-!I]P DcQ@y'ibDY_!@-*>cmíul]3/ymm.3pmϋ㑨xa++isb 7[m[WJF2$i4mAt/!e]tS_>ZM{_ui9(qTUSQ&Z#5g*}yu=vv *BDPI!E$dݽ~,qִP}q闶1Wzn^vޟsչ,Fɉ\>#-lU0rwj=d/ @R$j%;*A5đ2&8?!Ǧm_.N]N[omwGqeN*2x DxiaHo <~yzR(DTRp\qcml]G$&>/O4$Eu7}?ocp4ZI7-*qID24bǴ-4nngꤗ ˾"PPUBr#]}pEL'ʼiӣ39Ҿ9nx 1p(V7ܘlutI4k,-%%el3RTRߺDgu'H۝s ~ݛpySm޾ؘcKv>.GNzY~#Vc繾#}{R8V(H1ģ-MFfcU@=A1,K1& O/?gS?:}8wO=g/Tgb߳uuj6/mdC%NҞ<0xҵ%};x;#&urS6[Z=iZQ7>&w-OC749Haj$jY+w6<5:ɛ9 VY \QYT ଆ}u;.qE힝Qc *GdAAGP.̗Ke$|9MW YXA cEl5>2YhrʨKX{=Sn%]ܤsHH646Dn*pW)7rs{emw"@% 0$3[ n$%Z5>ҡE* ;=?ڹ8O LݓY&$$,pŜ=|_Ic|u=տݺ׵}~6qn|>خcET 3QT#M`!]ϙ-j+n.uy)Q)ӑIPs@zEލ Rq W>'y|G0ߋu({z\;%#6 iGyt^y$H>:u{'(HRnbAFZ9<4BTt{a5ySHj}NN?^N;ht#[n[wn-_NyZͳ궕V>HǶOwKE-B4f\lmK7c7]skŽ;# ̐K cJ#IAU.?ۙ}'fG`m?)3mxףU_kht)M!5kn7֐֖VW+<| KSڮ@=m2KETG]U:{~!w7O/s%]4{mo\8hfbaWZ( u*aӲ߽F)W?(^֙OjVDQj z1?/[g6_Dr>;rlnNYipNjQ~~f`ph5ݟ6.uG>߽i/cWgaZ,X<g!FJS]Avz7=lYc) ng(+Pȃ ~oHf҅ꯖ?:Χ/񫳍?mm~;);{o;p+3~5nJ.}Y-\rKK쪩PSIs۫jf/7&8@IvR'R^s5ԚE4k%A?1+㥟u7.=gh~Ҋmw=uJ͝9*|j5HdJEyX[WHp:*XwoN\omđ[[C6\^V蟍 {ڝ*hλvmUnkt09R(Y[o|üX6wwmhd 02U\UD8$Jb6ְI<wH9ΚW,f>=+xup;5;O%N2L٤T,0w{m(Z0B$r cptjsۋ SQ  Rȏ> nݟ&-[xb [FZ?ڻd6[stQtYh H\_AJ֕ ]Ekqү^}?o]OιMw\mT;{1?J'nm_oe5BO,aӴۦkq-1)vb҂̊PIf )Ev ]%CS 9;t7wG~S˵{ygaIeVuڧ{+g3{/`@TTTmoO[ewlƷ,%rRFeQGRI C"Cp ؎" z5=Ý]sۧ{twO ϔ_{tQ㨾/*Iy$o1"-@'MxD]9{csߺ^e7G]uu)k qB6ZC"K8l=&} is}|rh+~ZvX*XEtLWY3{rc66nveh[gm-7e`f s.; v0Q{tnI&lEٝϸ諱f6ÓllP'9]_TÔUk<4xRi^4._+B;cͺr|vWd)GhvүM5E& -rs n&GbZ(6{iכǭ2"F.zM BTUg.vMy4dM(}GLB0=SN'Ư;w'cϵ׍Ő^U-_a`))Ҋ|t-Br}YyKo \fNh AjV6#,]⚵Z׀)c,W|YN{7:7i|v#:ӱzDZvo\0O/A"D͍ <"exN[w/)MI+u*dPY An6 jtjEvo7yy᣼nkߥ1zAai ֽ06nǎ?[_/<>cjUrۗ>Pe+cl,ٲcz6pf#&ճȌ022{[ 7)ytuuIR 9 ΍Q4(X7oY!P PKH? ykbbC S?9x?/-zz<>-w4h<-4W^~㤟o?s~[M5Wϡ? ]7]1Eb1񷮺N7w6Ckwv]]䩰W|L%`?`ڶP˹n d:+Ȃ 0 kBFz~fku*TPp+˰?ȍmͅOwV#-޴=eͩ6??Gwfd0dC)vO3XNw$eFb^9ψJe zr]糑Wtb @+$u[_> 6mfv]њOBqeݽ6rj 68>?'WQ,XMO!|cYKIomo 0:[iHRkZE*˨*褷Űxf V xĊewz8{kX;}j{ahV@\He{YWG1ҳTK^mIc'|wg50Ooe $67kɖ6Z^Zne%vѲIYRjS^#KppF Y ("$>6'Ƕ^p9]ݟ%zk9foU:?[%ʊ 5%^Z9sWwerw$M1JʖP %I#< Q$M&R췛O ͤXMX^ER5'̨I&_av:?[/*>Lld]&iv6wunjS+6UaZI4!s%ֻ-f|!g%&2j4Ҡrnkh*CJOJQJS*Y(\aJo(phfff"W@1" *\lp5\f@Cf +jpQ*B*ph0@r0 'Hcke)ۏWD`66 !&SaS6Pg~ F b y ^ . a m n r  Z B~ AH,EN}~0Jb8P;Ht N y '!X!!!!"D"E"F"G"W"\"|"#C%&(++++,),7,D,Q,a,v,,,,,-- -L-d-|---.@.i......./!/*/\///0+0b0c0d001J1111282z22222203c333 4434L4M4N4y4579;<<<<==e=u========>???@ @ @*@G@d@@@@@A1AfAAAABOBBBBChCCCADDDDDDEEEEE$FtFFFFFFFF5HIsKMOOO1O>ONOYO}OOOOOOOP P1PAPfP{PPPPPPPPPQDQeQ/R_RsRRRR1SfSSSS#ThTTT UMUUUU VVVVVVWUWWWWWW?XqXXX;Y=Y>YiY[B]_^b_bcb{bbbbbbb c2cEcYcpccccccccc~ddd)eFeGeKeeeeeeOfoffffgKg{ggh7hlhhhiiiiiiii9jrjjkbkckdkkln oo>qrrrrss%s@sSscs{sssssssst.t=tNt\trtttttttquuv3v\vovvvvvvvEwlwwww_xixvxxxyy(y>yMyyy:z|zz%{?{X{x{{{{{{4|j|||||~A"9FSdw݆2K\hŇׇ+,0V1=>B)X~ ]<܍@z͎̎Ԏ S>?@f+Õ՘CDH\ișҙ0Sf̚#_ݛ(=ʝCTm'<ɟ$Р.Zˡ:;BϢP-./z@! LMQgï,EWrOe %Mܴݴ_m{#/;IX:b0Je-X|:λJQABGUj|4g6[ E-gpT&'+APd?{s\]d }~1Kj}~VW[K93.~ 9_8[pqr*\4>?CN^l0oY9MXF3&o YZaS ;` 8%p#/0123470000000000000000 0 0 0 000 000000000000000000 0 0 0 0 00000000000 0 0 0 0 0 0 000000000000000000000000000000 0 000000 0 00 0 0 0 0 0 0 0 00000000 0 000000000000000 0 0000 0 00 0 0 0 0 0 0 0 000000FFFFFF0F0FFFFFFFFFFFFFFFFFFFFFFFF0F0F0FF0FF0F0FF0F0FF 0F 0F 0F 0F0FFFFF0F0F0F0F0FF0F0F0F0FFFFFF0F0FFFF0FF0F0FFFFFF0F0FFFFFFFFFFFFFFFFF0F0F 0F 0F 0F0F0FF0F0F0FF0F0F0F0F0F0F0F0F0FFFFFF0F0F0F0F0FF0F0F0F0F0F0FFFFFF0F0FFFFFFFF0F0FFFFFFFFFFFFFFFFFFFFFFFFFF0F0FF0FF0F0F0F0FF0F0F0F0FF0F0F0F0FFFFFFFFFFFFFFFFFFFFFF0F 0F 0F 0F 0F 0F0F0F|||||0|0||||||||||||||||||||||||||||||0|0|0|||0|||0|0| 0| 0B| 0B| 0B| 0B| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0<| 0<| 0<| 0<| 0| 0| 0| 0| 0|0|0||||||0|0||||||||0|||||||||||||||||||||0|0|0|0|0|0|0|0||0||0|0|0|0|0|0|0|0|0|0|0|0|0||||||||||||||||0|0||||||0|0|//////0//////////////0/0//////0//0/0//0/0/0//0/0/0/0//0/0/0/0/////////////////0/////////0/0/////////////////////0///0////0////0///////0/0///////0/0//////////0// 0/ 0/ 0/ 0/0//0/0/0/0/0//0///////0/0/0/0/0///////0////////////0/0/0/0/0/0/0/0/0/0/0/0/0/0/0/0/0/0/0/0/0/0/0/0/0/ 0/ 0/ 0/ 0/ 0/ 0/ 0/ 0/ 0/ 0 / 0 / 0 / 0 / 0 / 0/0/0/////////0/////////////0/0/0//0/0/////0/0/0/0/0/0/0/0/0/0/0/0/0/0/0/0/0/0/0/0/0/0/ 0/ 0/ 0/ 0/ 0/ 0/ 0/ 0/ 0/ 0 / 0 / 0 / 0 / 0 / 0/00000@000@000@000@000@0@0@0@0@0@0@0@0@0@000 0000p0&SS6Pg~ F b y ^ . a m n r  Z B~ AH,EN}0Jb8P;Ht N y '!X!!!!"D"E"\"|"#C%&(++++,),7,D,Q,a,v,,,,,-- -L-d-|---.@.i......./!/*/\///0+0b0c0d001J1111282z22222203c333 4434N4579;<<<==e=u========>???@ @ @*@G@d@@@@@A1AfAAAABOBBBBChCCCADDDDDDEEEEE$FtFFFFF5HIsKMOO1O>ONOYO}OOOOOOOP P1PAPfP{PPPPPPPPPQDQeQ/R_RsRRRR1SfSSSS#ThTTT UMUUUU VVVVVVWUWWWWWW?XqXXX;Y>YiY[B]_^bcb{bbbbbbb c2cEcYcpccccccccc~ddd)eFeGeKeeeeeeOfoffffgKg{ggh7hlhhhiiiiiiii9jrjjkbkdkkln oo>qrrrrss%s@sSscs{sssssssst.t=tNt\trtttttttquuv3v\vovvvvvvvEwlwwww_xixvxxxyy(y>yMyyy:z|zz%{?{X{x{{{{{{4|j||~A"9FSdw݆2K\hŇׇ+,0V1=>B)X~ ]<܍@z͎̎Ԏ S>@f+Õ՘DH\ișҙ0Sf̚#_ݛ(=ʝCTm'<ɟ$Р.Zˡ:;BϢP-./z@! MQgï,EWrOe %Mܴݴ_m{#/;IX:b0Je-X|:λJQAGUj|4g6[ E-gpT&'+APd?{s\]d }~1Kj}~VW[K93.~ 9_8*\4CYXYa#/70c0c0c0c0c0c0c@0000<0 0>0090 0<0 0<0 0<0090c0c0c 0c 0c 0c 0c0c0c0c0c0c0c0c0c 0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c 0c 0c 0c 0c 0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c 0c 0c 0c 0c 0c 0c 0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c@0c0c0c0c0c0c0c 0c0c0c0c0c0c0c0c0c0c0c0c0c 0c0c0c 0c 0c 0c 0c 0c 0c 0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c 0c 0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c0c 0c0c0c0c0c0c0c0c0c0c0c0c0c 0c0c0c 0c 0c 0c 0c 0c 0c 0c 0c0c00h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h@0h@0h@0h@0h@0h@0h@0h0h0h0h 0h 0h 0h 0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h 0h 0h 0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h0h 0h 0h 0h 0h00^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^ 0^ 0^ 0^ 0^ 0^ 0^ 0 ^ 0 ^ 0 ^ 0 ^ 0^ 0^ 0^ 0^ 0^ 0^ 0^ 0^ 0^ 0^ 0^ 0 ^ 0 ^ 0 ^ 0 ^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^00|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|00000000000000000000000000000000000000000000000000000000000 0 0 0 0000000000000000@0@0@00000000000000000000000000000000000000000000 0 0 0 0 0 0 0 0 0 0  0 j00j00rj00rj00rj00rj00j00@0@0@0h@0@0@0@0@0@00CDh[0C0C000 @000 @000 0 HV F*!$,4.$/4<7B(DG/H(KMOjTfZ\]_Dabcd~gjttuvwz7~ʁP>9ګƭXP\Vz\`.6\ pP>at p J2!"!$W%&'*N-0"3c8{~*҃ԇΈd   "#$&')*+-.012345789:;GHIKLMNOPRZ[\^\H , 2F7 DgILO[bcftw~FeLhƭ$22Ea  B){!%(,/6FJQ]VXZ<>@w6CXXCXCXHOR!!8@0(  B S  ?6hr hs hs hTs ht ht hTt hu h>ҙҙܠ $$K E\7      !"&#$%')(*-+,./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~[[ vgg-99####(())),,D5D5e8p8}8888cHcHHHHHH!I,I,IyMMMMMMMMMzOPPVVVVVVYY[[e_e_bbbbnnnnnss}}u>>;;̑4.:DDڙڙΠΠ ,,X¦¦#I b7   !"$%&#')(*,-+./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~<Y*urn:schemas-microsoft-com:office:smarttagschmetcnv9*urn:schemas-microsoft-com:office:smarttagsStateB*urn:schemas-microsoft-com:office:smarttagscountry-region8*urn:schemas-microsoft-com:office:smarttagsCity=*urn:schemas-microsoft-com:office:smarttags PlaceName=*urn:schemas-microsoft-com:office:smarttags PlaceType9*urn:schemas-microsoft-com:office:smarttagsplace X 00.20.91279aCFFalseHasSpaceinmNegative NumberType SourceValueTCSCTrueUnitNameY  Y Y Y  Y Y Y  "%u{-5FO^f{}  : E \ a n x  # > B ] G ` a l n q  @GGT_lw~ &(*/0;?CDIVaq|~07FNl w &!*!W![!!!!! "$"C"G"K"M"V"X"["##r&x&++#,%,&,(,4,6,A,C,N,P,],`,i,k,m,u,,,,,,,,,,,--- ---..//$0*0<0B00001T2Z2223 3V3\3::<<======&=(=q=t=================?? @ @;Fo>xE}EO(O1O7O>OIONOROYObO}OOOOOOOOOOOOOPPP P$P1P8PAPGPfPnP{PPPPPPPPPPQQRRwTT[UhUUVXX^^``cbob{bbbbbbbbbc c%c2cS[frĚ̚ԚGMXbq|ӡ١ $/0LMQ\guïί",4ELWarjm[\'.3:?HMWٶBIjm8AR\15\`TW;=SXͽֽOQBDprGLU`jn|WYvx EG+1AHPXdlaopdk "1=KVjrtuQUCGNV^elx5CQUpNQ12733333333333333333333333ss3333333333333333333333333s3s3333333333333s333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333ss3333333333333333s33333333333333333333333333333333333333333333333333333333333333s333333333333333s33ss333g n r b W"\"+ ,v,,,--.D.b.h.i.m.......//*/2233=u== >>>>>>>?? @@DDEEEEFFFFGGRLLOOPPDQdQ R-RVV;Y>Yccccccd~dd)eGeKeeers3vOv\vhvvvvvy,y{{{{1u>B0ݛ˜ %(ȝɝʝϝ&';Q*OR#:/úߺ2J9Qgh?m<T{"j%./127127(Ktz.5 㺷.vm5hZ2 $7Y1K$v&nS'oJ$(QQ)VR4l-8k1 cK4ʿI8T>F6< ?B@NtikI"tOq v]Qlyn#Uܖy06X>IJva xH!b6"vh<iZv.}n\yZ y<@'zzR ,R|@xz^`zo(. H\H^H`\hH) \^`\hH. \^`\hH. 4\4^4`\hH)  \ ^ `\hH. | \| ^| `\hH.  \ ^ `\hH) \^`\hH.z^`zo(. H\H^H`\hH) \^`\hH. \^`\hH. 4\4^4`\hH)  \ ^ `\hH. | \| ^| `\hH.  \ ^ `\hH) \^`\hH.z^`zo(. H\H^H`\hH) \^`\hH. \^`\hH. 4\4^4`\hH)  \ ^ `\hH. | \| ^| `\hH.  \ ^ `\hH) \^`\hH.z^`zo(. H\H^H`\hH) \^`\hH. \^`\hH. 4\4^4`\hH)  \ ^ `\hH. | \| ^| `\hH.  \ ^ `\hH) \^`\hH.hh^h`o(. H\H^H`\hH) \^`\hH. \^`\hH. 4\4^4`\hH)  \ ^ `\hH. | \| ^| `\hH.  \ ^ `\hH) \^`\hH.k^`ko(. H\H^H`\hH) \^`\hH. \^`\hH. 4\4^4`\hH)  \ ^ `\hH. | \| ^| `\hH.  \ ^ `\hH) \^`\hH.uu^u`o(.U\U^U`\OJPJQJ^J. \^`\hH. \^`\hH. A \A ^A `\hH)  \ ^ `\hH.  \ ^ `\hH. -\-^-`\hH) \^`\hH.z^`zo(. U\U^U`\hH) \^`\hH. \^`\hH. A \A ^A `\hH)  \ ^ `\hH.  \ ^ `\hH. -\-^-`\hH) \^`\hH.uu^u`o(. U\U^U`\hH) \^`\hH. \^`\hH. A \A ^A `\hH)  \ ^ `\hH.  \ ^ `\hH. -\-^-`\hH) \^`\hH.z^`zo(. H\H^H`\hH) \^`\hH. \^`\hH. 4\4^4`\hH)  \ ^ `\hH. | \| ^| `\hH.  \ ^ `\hH) \^`\hH.z^`zo(.f>f^f`>OJPJQJ^J) \^`\hH. \^`\hH. 4\4^4`\hH)  \ ^ `\hH. | \| ^| `\hH.  \ ^ `\hH) \^`\hH.uu^u`o(.U\U^U`\OJPJQJ^J. \^`\hH. \^`\hH. A \A ^A `\hH)  \ ^ `\hH.  \ ^ `\hH. -\-^-`\hH) \^`\hH.hh^h`OJPJQJ^J.  ^ `o(. \^`\hH. \^`\hH. 4\4^4`\hH)  \ ^ `\hH. | \| ^| `\hH.  \ ^ `\hH) \^`\hH.k^`ko(.f>f^f`>o() \^`\hH. \^`\hH. 4\4^4`\hH)  \ ^ `\hH. | \| ^| `\hH.  \ ^ `\hH) \^`\hH.hh^h`o(. H\H^H`\hH) \^`\hH. \^`\hH. 4\4^4`\hH)  \ ^ `\hH. | \| ^| `\hH.  \ ^ `\hH) \^`\hH.^`o(. \^`\hH) b\b^b`\hH.  \ ^ `\hH.  \ ^ `\hH) N \N ^N `\hH.  \ ^ `\hH. \^`\hH) :\:^:`\hH.hh^h`o(. H\H^H`\hH) \^`\hH. \^`\hH. 4\4^4`\hH)  \ ^ `\hH. | \| ^| `\hH.  \ ^ `\hH) \^`\hH.z^`zo(. H\H^H`\hH) \^`\hH. \^`\hH. 4\4^4`\hH)  \ ^ `\hH. | \| ^| `\hH.  \ ^ `\hH) \^`\hH.z^`zo(. H\H^H`\hH) \^`\hH. \^`\hH. 4\4^4`\hH)  \ ^ `\hH. | \| ^| `\hH.  \ ^ `\hH) \^`\hH.z^`zo(. H\H^H`\hH) \^`\hH. \^`\hH. 4\4^4`\hH)  \ ^ `\hH. | \| ^| `\hH.  \ ^ `\hH) \^`\hH.hh^h`o(. H\H^H`\hH) \^`\hH. \^`\hH. 4\4^4`\hH)  \ ^ `\hH. | \| ^| `\hH.  \ ^ `\hH) \^`\hH.\^`\B*CJo(phfff. H\H^H`\hH) \^`\hH. \^`\hH. 4\4^4`\hH)  \ ^ `\hH. | \| ^| `\hH.  \ ^ `\hH) \^`\hH.z^`zo(.f>f^f`>OJPJQJ^J) \^`\hH. \^`\hH. 4\4^4`\hH)  \ ^ `\hH. | \| ^| `\hH.  \ ^ `\hH) \^`\hH.k^`ko(. H\H^H`\hH) \^`\hH. \^`\hH. 4\4^4`\hH)  \ ^ `\hH. | \| ^| `\hH.  \ ^ `\hH) \^`\hH.z^`zo(. H\H^H`\hH) \^`\hH. \^`\hH. 4\4^4`\hH)  \ ^ `\hH. | \| ^| `\hH.  \ ^ `\hH) \^`\hH.z^`zo(. H\H^H`\hH) \^`\hH. \^`\hH. 4\4^4`\hH)  \ ^ `\hH. | \| ^| `\hH.  \ ^ `\hH) \^`\hH.z^`zo(.  ^ `OJPJQJ^J)^`o( \^`\hH. 4\4^4`\hH)  \ ^ `\hH. | \| ^| `\hH.  \ ^ `\hH) \^`\hH.hh^h`o(. H\H^H`\hH) \^`\hH. \^`\hH. 4\4^4`\hH)  \ ^ `\hH. | \| ^| `\hH.  \ ^ `\hH) \^`\hH. z^`zB*o(ph. H\H^H`\hH) \^`\hH. \^`\hH. 4\4^4`\hH)  \ ^ `\hH. | \| ^| `\hH.  \ ^ `\hH) \^`\hH.z^`zo(.M^`Mo() :\:^:`\hH. \^`\hH. \^`\hH) & \& ^& `\hH.  \ ^ `\hH. n \n ^n `\hH) \^`\hH.^`o(. \^`\hH) \^`\hH. C\C^C`\hH.  \ ^ `\hH)  \ ^ `\hH. / \/ ^/ `\hH. \^`\hH) w\w^w`\hH.k1nF6<06XI8?Bn#UikI5 Zvh\y5h.<i$7,R|K$R4l-ZvH!btzcK4IJvaQQ)O'z yv]QoJ$(K~8        f)N^        L        Xx        "PG        P(        ClWdy       Z        }#        0HĈ        iqΰ       CL       JD2>rP?       .\       "zo        hg        (         R        R        *<        "tN        _        iz       7        N!        H Z        ZZ\fhy      Dk                 lSLֻ       "        ^--]!qhQu$*bB{io"$r{9=4ano/{ }"K f 3~ I s  ' 0 m ~ 1 \\+#0[3*4>g]cm.D1Z#*Lck#MW mix:F1l+X;;gR ,#'!OA$8 $!E!J!vc!T","N9";|"2#Ls#2)$)$'% &us&'?'*B'w(?(o_(VC)}* +1+E+*K+Sq+Ds+l$,4D,M|,(- ./I/@p/0ln0F1 1Bc1w122>2b2s253<3y3*4,c4+5C6F6=X6c$7Bx7O8Iw8CH9::RV:f:tx:G;?;T=>> Y>[>2y>Ab?}?;jA"B<1Bo>CWC,oC"DZ8D3DD>IDWnD)qDqDBEFF&FCBFwFpG'HOtH I+Ib-I@IlIZJJ K!@K^LD/M;MJ/N5NO7OhOlOPgPX{P1 QQ Q=QPjQ<"RQR^RS`St$SESxS/T:T8]TrUA&UykU/BV"W9WUW\Wv1XUcX~ YY!Y Z+Z6yZ[k[Z5[&\\i \8\ \u[\]\r\3u\.]C]t]^M_r`y`0a acUaHua%Nbacc6cU;cUc+Zczrde3e-@eUeNfI!f[f g[gzg IiN[i!hiliziCj jKjcjke[kskl*\l!2m0n2n+oM&o(o7p:pBp+jpqpG+q@0qo>qn r\,r&`rprshu6u3cu"vDwv^w{#xKx-LxAPx yxyi{{N@{d{ l{A|K|d}f}.}H}Y} ~.~/Y~^~+n~u~ H%PQ_( FMxG}Gy%gxeDgE^a&>^im5H &Z4WQNZ^w?%).g;gp(5q@@V\w/2`F~a3;afry]V0n]dGp}48Q|'qXCY,Zla ,Yh*n0{$nADb-9R0*V{ PI,?H#SSd"jraT}SXt9u:"r$GKo ? VLpcgwBdgsz2;16 NU]w[k,#bg>A@ r5r= wY COg~?poq{d$7r_*Na4>^/|sQ"ZC-79o ApDF8XkX^`cbK,\]';.fh`;6ET_&fxz?%5%<%eH_"rlXU; &AN#oJ P-A\v@2?R>L3y}u.7tvCCJoE t3@%yjk@n&q/c ?@.ELSXrd]  &wR$w|xz]6WA2D7TLv0<]6s`fI@\olKaG_TIjK~I)v&=VZkQz05Uk4B;F;Ro6qY.kv05,CY/RJa&^>yUA0,*/b0c0122@AABDD7m@4l    "+,.014<=?@DFGOPQSWZbefikqvz|͎͏͙͚͐͛͘͜͝͞;;;MMMMMMMMMMMM]]]]]]]]\\\\\ZA6@4@D@*,.`@4p@BD@JL@Z\`@fj@tvx@ @,@<@\@l@@@@@ @ @@@  @,@D@&(,h@@z@UnknownGz Times New Roman5Symbol3& z Arial7&  Verdana;[SOSimSunO SILDoulosIPASymbol 1hăfăf ' '!-!),.:;?]}    & 6"0000 0 0 00000 =@\]^([{  0 0 00000;[d 2QHX?*\l2 ,{NR $ReMS Userlilu                          Oh+'0d   , 8DLT\ڶ ĶжMS UserNormallilu2Microsoft Office Word@@ X@ X '՜.+,D՜.+, X`px MS User'  8@ _PID_HLINKSAhWA)http://www.chinaacc.com/demo/english.htm(* Chttp://www.chinaacc.com/wangxiao/gonggao/english/2008englishfa.htm[X.http://www.chinaacc.com/login/pay_reg_new.asp[X.http://www.chinaacc.com/login/pay_reg_new.asp  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXY[\]^_`acdefghipRoot Entry F4 XrData `W1TableٚWordDocument2SummaryInformation(ZDocumentSummaryInformation8bCompObjm  FMicrosoft Office Word ĵ MSWordDocWord.Document.89q